The original disclosure in Japanese was released on May 14, 2020 at 16:00 (GMT+9)

# Consolidated Financial Statements for the Year Ended March 31, 2020
# FY2020(April 1, 2019 - March 31, 2020) [UNAUDITED]


Company name: Takara Holdings Inc.
Stock exchange listing: Tokyo Stock Exchange (1st section)
Code Number: 2531
URL: https://www.takara.co.jp/
Company representative: Mutsumi Kimura, President
Contact: Masakazu Usami, General Manager of Financial & Investor Relations Dept.
TEL : (075)241-5124


Scheduled date of general shareholders' meeting: June 26, 2020
Scheduled date of starting delivery of dividends: June 29, 2020

Notes: 1. The accompanying financial statements have been prepared in accordance with accounting principles and practices generally accepted in Japan.
2. Amounts are rounded down to the nearest million yen.

## 1. Results for the year ended March 31, 2020(April 1, 2019 – March 31, 2020)

### (1) Consolidated Operating results

Note: Percentages indicated changes from the previous fiscal year.

| | Year ended March 31, 2020 | | Year ended March 31, 2019 | |
|---|---|---|---|---|
| | (Millions of yen) | (%) | (Millions of yen) | (%) |
| Net sales | 281,191 | 1.4 | 277,443 | 3.5 |
| Operating income | 15,836 | (11.1) | 17,804 | 14.0 |
| Ordinary income | 16,269 | (11.4) | 18,359 | 14.1 |
| Net income (loss) attributable to owners of the parent | 8,980 | (13.7) | 10,411 | (5.6) |
| Net income per share (Yen) | 45.11 | | 52.15 | |
| Fully diluted net income per share (Yen) | - | | - | |
| Return on equity | | 6.1 | | 7.1 |
| Ordinary income to total assets ratio | | 5.7 | | 6.4 |
| Operating income to net sales ratio | | 5.6 | | 6.4 |
| Note: Comprehensive income | 6,467 | (10.8) | 7,249 | (53.8) |
| Reference: Income (loss) from equity method investment | 81 | | 36 | |

### (2) Consolidated Financial position

| | As of March 31, 2020 | As of March 31, 2019 |
|---|---|---|
| | (Millions of yen) | (Millions of yen) |
| Total assets | 283,882 | 287,106 |
| Net assets | 181,329 | 179,795 |
| Equity ratio (%) | 52.1 | 51.6 |
| Net assets per share (Yen) | 747.39 | 742.36 |
| Reference: Equity | 147,762 | 148,197 |

### (3) Consolidated Cash flow

| | Year ended March 31, 2020 | Year ended March 31, 2019 |
|---|---|---|
| | (Millions of yen) | (Millions of yen) |
| Cash flow from operating activities | 11,744 | 13,508 |
| Cash flow from investing activities | (3,690) | (9,213) |
| Cash flow from financing activities | (11,653) | (4,243) |
| Cash and cash equivalents, end of year | 44,541 | 48,580 |

## 2. Dividends

| | Dividend per share (Yen) | | |
|---|---|---|---|
| | Year ended March 31, 2019 | Year ended March 31, 2020 | Year ending March 31, 2021(Forecast) |
| First quarter end | - | - | - |
| Second quarter end | - | - | - |
| Third quarter end | - | - | - |
| Year end | 18.0 | 20.00 | 20.00 |
| Annual | 18.0 | 20.00 | 20.00 |
| Total dividend (Millions of yen) | 3,593 | 3,954 | |
| Payout ratio (%) | 34.5 | 44.3 | 77.5 |
| Dividend on equity (%) | 2.5 | 2.7 | |

**3. Forecast for the year ending March 31, 2021 (April 1, 2020 – March 31, 2021)**

Note: Percentages indicated changes from the same period of the previous fiscal year.

| | Six months ending September 30, 2020 | | Year ending March 31, 2021 | |
|---|---|---|---|---|
| | (Millions of yen) | (%) | (Millions of yen) | (%) |
| Net sales | 120,000 | (12.7) | 270,000 | (4.0) |
| Operating income | 300 | (96.1) | 10,000 | (36.9) |
| Ordinary income | 400 | (94.9) | 10,200 | (37.3) |
| Net income attributable to owners of the parent | 0 | (100.0) | 5,100 | (43.2) |
| Net income attributable to owners of the parent per share (Yen) | 0.00 | | 25.80 | |

**4. Others**

(1) Material changes in subsidiaries during this period
(Changes in specified subsidiaries that caused a change in the scope of consolidation) : No

(2) Changes in accounting policies, accounting estimates and retrospective restatement
1) Changes based on revisions of accounting standard : Yes
2) Changes other than ones based on revisions of accounting standard : No
3) Changes in accounting estimates : No
4) Restatement : No

(3) Number of outstanding shares (common stock)
1) Number of outstanding shares at year end (Treasury stocks are included):
As of March 31, 2020 199,699,743 shares
As of March 31, 2019 201,699,743 shares
2) Number of treasury stocks at year end:
As of March 31, 2020 1,995,163 shares
As of March 31, 2019 2,069,706 shares
3) Average number of outstanding shares:
Year ended March 31, 2020 199,062,788 shares
Year ended March 31, 2019 199,630,226 shares

Contents of the attached document


1. Overview of Financial Results……... 2
(1) Overview of Financial Results for the Fiscal Year under Review……..…… 2
(2) Overview of Financial Position for the Fiscal Year under Review…… 5
(3) Overview of Cash Flows for the Fiscal Year under Review……..……..…. 6
(4) Future Outlook……..……..…. 6
2. Basic concept on selection of accounting standards……..…… 7
3. Consolidated Financial Statements and Primary Notes……..…… 8
(1) Consolidated Balance Sheets……...…… 8
(2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income……...…… 10
Consolidated Statements of Income……..…… 10
Consolidated Statements of Comprehensive Income…….. 11
(3) Consolidated Statements of Changes in Net Assets……. 12
(4) Consolidated Statements of Cash Flows……... 14
(5) Notes to Consolidated Financial Statements…… 15
(Notes on Premise of Going Concern)…….. 15
(Changes in Accounting Policies)……..…. 15
(Segment Information)…….. 15
(Per Share Information)…… 18
(Significant Subsequent Events)……... 19


○Supplement for the Consolidated Financial Statements

1.Overview of Financial Results

(1) Overview of Financial Results for the Fiscal Year under Review

In the fiscal year under review, ended March 31, 2020, although the Japanese economy maintained a moderate recovery, personal spending remained weak due to the prolonged effect of the consumption tax hike implemented in October 2019. Overseas, the global economic outlook remained uncertain, due to such factors as the recent growing spread of the COVID-19, in addition to the developments in the trade issues between the U.S. and China and the increasing uncertainties in the Middle East.

Under these economic circumstances, under the Takara Group Medium-Term Management Plan for FY2021-2023, which is the last step towards achieving its long-term Takara Group Vision 2020, the Company has aimed to build up a great number of fields in which it can beat competitors and establish a balanced business foundation able to grow revenues significantly, no matter what environmental changes occur, by further increasing the overseas sales ratio together with having a full product line-up and many products with a competitive edge, both in Japan and overseas.

As a result, in the fiscal year under review, ended March 31, 2020, net sales were up 1.4% year on year to ¥281,191 million. Gross profit fell 0.1% year on year to ¥108,617 million. Operating income decreased by 11.1% year on year to ¥15,836 million while ordinary income fell 11.4% year on year to ¥16,269 million. Net income attributable to owners of the parent decreased by 13.7% year on year to ¥8,980 million.

Results by business segment were as follows.

**[Takara Shuzo]**

The challenging business environment is expected to continue as the trend of decrease in total consumption of alcoholic beverages persists due to the impact of the decline and aging of the population in Japan among other factors.

In this environment, Takara Shuzo continued to develop products differentiated by its technology in addition to strengthening its product development system in order to respond to diversifying consumer needs in a timely and prompt manner and focusing efforts on increasing competitiveness in the alcoholic beverage and seasoning categories by expanding its product range. Takara Shuzo also worked on improving its profit ratio by increasing the sales ratio of high value added products while striving to strengthen safety assurance and quality control systems for raw materials in order to supply safe and secure products as a food manufacturer.

The segment's sales and other information are as follows:

**[Alcoholic beverages]**

For *ko*-type shochu, Takara Shuzo worked on expanding sales of *Takara Shochu for Premium Lemon Sour*, which is the perfect shochu base for premium lemon sour made at home. For honkaku shochu, Takara Shuzo renewed and launched *Ikkomon (100% sweet-potato-base)* by carefully aging it in a stone warehouse, which was newly constructed in Kurokabegura, Miyazaki. The product quality features the true flowery aroma of sweet potatoes and a refined, clean taste.

For sake, Takara Shuzo worked on expanding sales of *Sho Chiku Bai Ten* for consumption at home and *Sho Chiku Bai Gokai* for the commercial market. For *Mio*, Takara Shuzo launched *Sho Chiku Bai Shirakabegura Mio ICHIKA Sparkling Sake Ichigo no Yona Kaori, Sparkling Sake Banana no Yona Kaori,* which is a brand of sparkling sake that can be enjoyed on a daily basis.

For light alcohol refreshers, Takara Shuzo paid most attention to expanding sales of dry flavored chu-hi *Takara Shochu Highball*, positioned as a flagship brand. In addition, Takara Shuzo worked on expanding sales of *Takara Gokujo Lemon Sour*, a premium lemon sour that makes use of great tasting cask-aged shochu. Furthermore, Takara Shuzo strove to further vitalize the light alcohol refresher market such as by launching "matcha alcohol refreshers" including *Takara Gokujo Matcha-Hi*, which is a readily enjoyable, authentic "matcha-hi." As a result, total alcoholic beverages net sales decreased 0.3% year on year to ¥119,645 million.

**[Seasonings]**

In seasonings, Takara Shuzo worked on developing and nurturing products such as those based on user needs and high value added ones differentiated by its unique technology. For Hon-Mirin and cooking sake, Takara Shuzo renewed packaging design in order to strengthen the emphasis of the culinary effects of "power of alcohol." Takara Shuzo also continued to work on expanding sales of food seasonings such as fermented seasonings. As a result, overall net sales of seasonings increased 3.1% year on year to ¥24,311 million.

**[Raw alcohol, etc.]**

Takara Shuzo worked to expand sales of raw alcohol for alcoholic beverages and industrial alcohol. As a result, raw alcohol, etc. net sales increased 3.9% year on year to ¥9,183 million.

As a result, net sales for the Takara Shuzo Group rose 0.4% year on year to ¥153,141 million. Cost of sales increased by 1.5% year on year to ¥92,822 million, due to an increase in the price of raw materials. Consequently, gross profit fell 1.1% year on year to ¥60,318 million. SG&A expenses were up by 2.0% year on year to ¥56,142 million, due to increases in promotion and transportation expenses and other expenses. Accordingly, the Takara Shuzo Group recorded operating income down 29.8% year on year to ¥4,175 million.

**(Takara Shuzo International Group)**

The Takara Shuzo International Group expanded the Overseas Alcoholic Beverages Business, which entails exports from Japan and the manufacture and sale of alcoholic beverages in overseas locations, and the Japanese Food Wholesale Business in overseas markets, through which it sells Japanese food ingredients to Japanese food restaurants and retailers outside Japan. With global market for Japanese foods growing larger in a trend that is expected to continue, the Takara Shuzo International Group worked on business activities with the aim of establishing itself as a leading company in the global Japanese alcoholic beverages and food markets by letting the world know about the great taste of traditional Japanese alcoholic beverages such as sake and shochu in addition to Japanese food.

The segment's sales and other information are as follows:

**Overseas Alcoholic Beverages Business**

The Takara Shuzo International Group increased sales by continuously working on enhancing the product line-up of sake, including local products in the U.S. and China that utilizes the local advantages and high value added export products from Japan. Particularly in China, sales of sake exported from Japan trended strongly. In addition, due mainly to an increase in whiskey, which remained in high demand worldwide, net sales rose 5.6% year on year to ¥11,365 million.

**Japanese Food Wholesale Business in overseas markets**

Amid the continued expansion of the Japanese food market across the world, the Takara Shuzo International Group continued to work on expanding sales offices and logistics bases. Mutual Trading Co., Inc. in North America, which has the largest market size, and FOODEX S.A.S., Tazaki Foods Ltd., and Cominport Distribución S.L. in Europe, where the Group has the top share, increased sales, and net sales rose 6.4% year on year to ¥73,371 million.

In addition, TOKYO MUTUAL TRADING CO., LTD., which conducts export sales of food products, etc. mainly in the U.S., was newly welcomed into the Group, achieving the enhancement of relationships with procurement sources and expansion of product development function and product supply function for the U.S.

As a result, net sales for the Takara Shuzo International Group rose 6.3% year on year to ¥82,765 million. Cost of sales increased 7.4% year on year to ¥58,882 million due mainly to an increase in procurement costs from exchange rate fluctuations in the Japanese Food Wholesale Business in overseas markets, and gross profit increased 3.8% year on year to ¥23,883 million. SG&A expenses were up 10.1% year on year to ¥20,351 million due mainly to increases in personnel expenses and logistics expenses. Accordingly, the Takara Shuzo International Group recorded operating income down 22.1% year on year to ¥3,532 million.

**(Takara Bio Group)**

The Takara Bio Group has promoted efforts with the aim of enhancing its standing as a global enterprise and regenerative medical products company and to achieve prodigious growth.

**Bioindustry business**

As the Takara Bio Group's core business, the Bioindustry business mainly provides products and services that support research and development activities in biotechnology-related fields as such activities become increasingly widespread.

In the Bioindustry business, although sales of scientific instruments declined year on year, sales of mainstay research reagents and contract research services increased year on year, in the fiscal year under review ended March 31, 2020. As a result, net sales in the Bioindustry business increased 2.2% year on year to ¥32,269 million.

**Gene Therapy business**

In the Gene Therapy business, the Takara Bio Group promoted the clinical development of gene therapy for cancer and other diseases utilizing the oncolytic virus canerpaturev (C-REV); the RetroNectin® Method, a proprietary and highly-efficient gene transduction technology; the RetroNectin® expansion-culture system, a highly efficient lymphocyte propagation technology; and a genetically engineered T-cell therapy utilizing siTCR™ technology among others.

In the fiscal year under review, ended March 31, 2020, the Gene Therapy business recorded net sales that included consideration in relation to a domestic co-development and exclusive sales agreement for NY-ESO-1 siTCR® gene therapy product and CD19-CAR gene therapy product and investigational products based on the agreement. As a result, net sales in the Gene Therapy business were down 6.0% year on year to ¥2,295 million.

As a result, net sales for the Takara Bio Group fell 3.6% year on year to ¥34,565 million. Cost of sales decreased by 11.2% year on year to ¥13,459 million. Consequently, gross profit rose 2.0% year on year to ¥21,105 million. SG&A expenses were down by 2.6% year on year to ¥14,830 million, due to decreases in research and development expenses and other expenses. Accordingly, operating income increased by 14.8% year on year to ¥6,274 million.

**(Other)**

The Other segment includes the real estate leasing business and the distribution business of Group companies in Japan. Net sales of the Other segment declined 2.9% year on year to ¥31,801 million as Takara Healthcare Inc. was excluded from the scope of consolidation during the previous fiscal year accompanying the sale of all shares in that company. Cost of sales declined by 0.4% year on year to ¥27,733 million. Consequently, gross profit decreased by 16.8% year on year to ¥4,067 million. SG&A expenses fell by 30.2% year on year to ¥2,049 million. As a result, operating income increased by 3.3% year on year to ¥2,018 million.

Breakdown of sales results by product category

| Segment / Product category | Previous Fiscal Year (From April 1, 2018 to March 31, 2019) Amount (Millions of yen) | Fiscal Year under Review (From April 1, 2019 to March 31, 2020) Amount (Millions of yen) | YoY Comparison (%) |
|---|---|---|---|
| Takara Shuzo | | | |
| Shochu | 53,382 | 49,728 | 93.2 |
| Sake | 21,394 | 20,488 | 95.8 |
| Light-alcohol refreshers | 38,777 | 43,023 | 110.9 |
| Other alcoholic beverages | 6,482 | 6,405 | 98.8 |
| Alcoholic beverages total | 120,037 | 119,645 | 99.7 |
| *Hon Mirin* | 13,869 | 13,980 | 100.8 |
| Other seasonings | 9,714 | 10,330 | 106.3 |
| Seasonings total | 23,583 | 24,311 | 103.1 |
| Raw alcohol, etc. | 8,836 | 9,183 | 103.9 |
| Total | 152,457 | 153,141 | 100.4 |
| Takara Shuzo International Group | | | |
| Overseas Alcoholic Beverages Business | 10,758 | 11,365 | 105.6 |
| Japanese Food Wholesales Business in overseas markets | 68,954 | 73,371 | 106.4 |
| Other | 62 | 204 | 326.8 |
| Elimination of intraGroup transaction on consolidation | (1,940) | (2,175) | — |
| Total | 77,834 | 82,765 | 106.3 |
| Takara Bio Group | 35,841 | 34,565 | 96.4 |
| Reported segment total | 266,132 | 270,472 | 101.6 |
| Other | 32,742 | 31,801 | 97.1 |
| Segment total | 298,875 | 302,273 | 101.1 |
| Sales not allocated to business segments and intersegment transactions | (21,431) | (21,082) | — |
| **Total** | 277,443 | 281,191 | 101.4 |

Notes: Amounts include alcohol tax but do not include consumption tax.

(2) Overview of Financial Position for the Fiscal Year under Review

(Assets)

At the end of the fiscal year under review, current assets totaled ¥168,820 million, a decrease of ¥6,191 million compared with that at the end of the previous fiscal year. This was primarily due to decreases in cash and deposits of ¥2,150 million and securities of ¥8,736 million and increases in notes and accounts receivable – trade of ¥1,777 million and merchandise and finished goods of ¥1,695 million. Noncurrent assets were ¥115,061 million, an increase of ¥2,966 million compared with that at the end of the previous fiscal year. This was primarily due to an increase in property, plant and equipment of ¥9,258 million, including an increase in buildings and structures, a decrease in intangible assets of ¥1,214 million, including a decrease in goodwill, and a decrease in investment securities of ¥4,422 million.

As a result, total assets were ¥283,882 million, a decrease of ¥3,224 million compared with that at the end of the previous fiscal year.

(Liabilities)

At the end of the fiscal year under review, current liabilities totaled ¥55,466 million, a decrease of ¥2,355 million compared with that at the end of the previous fiscal year. This was primarily due to decreases in short-term loans payable of ¥5,173 million and accrued alcohol tax of ¥2,534 million, and an increase in current portion of bonds of ¥5,000 million due to transfer from noncurrent liabilities. Noncurrent liabilities were ¥47,086 million, a decrease of ¥2,402 million compared with that at the end of the previous fiscal year. This was primarily due to decreases in bonds of ¥5,000 million and deferred tax liabilities of ¥1,328 million, and an increase in lease obligations of ¥3,181 million.

As a result, total liabilities were ¥102,553 million, a decrease of ¥4,758 million compared with that at the end of the previous fiscal year.

(Net Assets)

At the end of the fiscal year under review, total net assets were ¥181,329 million, an increase of ¥1,534 million compared with that at the end of the previous fiscal year. This was primarily due to an increase in retained earnings of ¥3,776 million and a decrease in valuation difference on available-for-sale securities of ¥2,689 million.

As a result, the equity ratio totaled 52.1%, compared with 51.6% at the end of the previous fiscal year.

(3) Overview of Cash Flows for the Fiscal Year under Review

Net cash provided by operating activities decreased ¥1,763 million year on year to ¥11,744 million primarily due to profit before income taxes of ¥15,643 million, depreciation and amortization of ¥7,626 million, increase in notes and accounts payable – trade of ¥1,291 million, increase in inventories of ¥3,159 million, decrease in accrued alcohol tax of ¥2,534 million, and income taxes paid of ¥4,955 million.

Net cash used in investing activities resulted in expenditure of ¥3,690 million, a decrease in expenditure of ¥5,522 million compared with that of the previous fiscal year primarily due to payments into time deposits of ¥6,785 million, proceeds from the withdrawal of time deposits of ¥10,564 million, proceeds from sales and redemption of securities of ¥11,507 million, purchase of property, plant and equipment and intangible assets of ¥12,121 million, and proceeds from sales of investment securities of ¥1,636 million.

Net cash used in financing activities resulted in expenditure of ¥11,653 million, an increase of ¥7,410 million compared with that of the previous fiscal year primarily due to repayments of long-term loans payable of ¥5,160 million, purchase of treasury stock of ¥2,000 million, and cash dividends paid of ¥3,589 million.

As a result, cash and cash equivalents at fiscal year-end, including effect of exchange rate change on cash and cash equivalents, stood at ¥44,541 million, down ¥4,039 million from the previous fiscal year-end.

(4) Future Outlook

The domestic environment surrounding the Takara Group is expected to grow increasingly harsh in the future, including long-term contraction of the alcoholic beverages market resulting from an aging and declining population as well as younger generations consuming less alcohol, a hike in prices of foods and resources due to an increase in the world's population, and personnel expenses and logistics expenses remaining high within Japan. Meanwhile, there are opportunities for growth including the expansion of the bioindustry market and the worldwide Japanese alcoholic beverage and food market overseas. However, tensions are growing in the Middle East and around trade issues including those between the U.S. and China. In addition, responsibilities of companies for creating a sustainable society is further increasing, as responses to various social and environmental issues are being required on a global scale.

In light of these circumstances, the Group has formulated its long-term management vision, TaKaRa Group Challenge for the 100th, with the fiscal year ending March 31, 2026 as its final year, and launched the Takara Group Medium-Term Management Plan for FY2021-2023, a three-year medium-term management plan with the fiscal year ending March 31, 2023 as the final year, as the first step in the Group's action plans.

Going forward, the Takara Group will aim for sustainable growth and a leap forward, while increasing the Takara Group's presence domestically and overseas, by further improving its technical capabilities, product capabilities and brand power, and providing diverse values in the Japanese alcoholic beverage and food market and the life science industry, with a view to achieving "Smiles in Life" in the long-term management vision.

As regards the outlook for results for the following fiscal year, the fiscal year ending March 31, 2021, the Group is forecasting net sales of ¥270,000 million, operating income of ¥10,000 million, ordinary income of ¥10,200 million, and net income attributable to owners of the parent of ¥5,100 million. The details of the consolidated results forecasts and the results forecasts for each segment are described on pages 10/15-13/15 in "Supplement for the Consolidated Financial Statements."

In addition, for details on the long-term management vision and the medium-term management plan, please refer to "Formulation of the Long-Term Management Vision, TaKaRa Group Challenge for the 100th" announced today.

The outlook for results for the following fiscal year was formulated based on an assumption that the impact of COVID-19 will continue until around July 2020, and actual results may differ due to a variety of factors going forward.

**2. Basic concept on selection of accounting standards**

The Takara Group has a policy to prepare the Consolidated Financial Statements in accordance with the Japanese GAAP for the time being, taking into consideration comparability of the Consolidated Financial Statements across periods and companies.

As regards the application of the International Financial Reporting Standards, the Takara Group will take appropriate actions, taking into account the situations in Japan and other countries.

## 3. Consolidated Financial Statements and Primary Notes

### (1) Consolidated Balance Sheets

(Millions of Yen)

| | As of Mar. 31, 2019 | As of Mar. 31, 2020 |
|---|---|---|
| Assets | | |
| Current assets | | |
| Cash and deposits | 49,415 | 47,265 |
| Notes and accounts receivable-trade | 52,892 | 54,670 |
| Electronically recorded monetary claims-operating | 6,887 | 6,347 |
| Securities | 16,089 | 7,352 |
| Merchandise and finished goods | 40,600 | 42,295 |
| Work in process | 1,341 | 1,801 |
| Raw materials and supplies | 4,093 | 4,879 |
| Other | 4,006 | 4,515 |
| Allowance for doubtful accounts | (315) | (307) |
| Total current assets | 175,011 | 168,820 |
| Noncurrent assets | | |
| Property, plant and equipment | | |
| Buildings and structures | 52,808 | 59,337 |
| Accumulated depreciation | (34,101) | (35,189) |
| Buildings and structures, net | 18,706 | 24,148 |
| Machinery, equipment and vehicles | 80,774 | 86,331 |
| Accumulated depreciation | (68,515) | (69,661) |
| Machinery, equipment and vehicles, net | 12,259 | 16,670 |
| Land | 18,559 | 18,337 |
| Lease assets | 1,025 | 1,833 |
| Accumulated depreciation | (511) | (586) |
| Lease assets, net | 514 | 1,247 |
| Construction in progress | 6,105 | 1,531 |
| Other | 15,706 | 21,262 |
| Accumulated depreciation | (11,274) | (13,362) |
| Other, net | 4,432 | 7,900 |
| Total property, plant and equipment | 60,576 | 69,835 |
| Intangible assets | | |
| Goodwill | 12,400 | 11,750 |
| Other | 7,514 | 6,950 |
| Total intangible assets | 19,914 | 18,700 |
| Investments and other assets | | |
| Investment securities | 26,143 | 21,720 |
| Net defined benefit asset | 877 | 651 |
| Deferred tax assets | 1,648 | 1,807 |
| Other | 2,995 | 2,414 |
| Allowance for doubtful accounts | (60) | (69) |
| Total investments and other assets | 31,603 | 26,525 |
| Total noncurrent assets | 112,094 | 115,061 |
| Total assets | 287,106 | 283,882 |

(Millions of Yen)

| | As of Mar. 31, 2019 | As of Mar. 31, 2020 |
|---|---|---|
| Liabilities | | |
| Current liabilities | | |
| Notes and accounts payable-trade | 16,374 | 16,440 |
| Short-term loans payable | 9,960 | 4,787 |
| Current portion of bonds payable | - | 5,000 |
| Accrued alcohol tax | 10,224 | 7,690 |
| Accrued expenses | 5,809 | 5,511 |
| Income taxes payable | 1,879 | 1,886 |
| Provision for bonuses | 2,579 | 2,513 |
| Provision for sales promotion expenses | 1,921 | 2,094 |
| Other | 9,072 | 9,543 |
| Total current liabilities | 57,822 | 55,466 |
| Noncurrent liabilities | | |
| Bonds payable | 25,000 | 20,000 |
| Long-term loans payable | 5,415 | 5,448 |
| Lease obligations | 357 | 3,538 |
| Deferred tax liabilities | 2,907 | 1,578 |
| Net defined benefit liability | 8,757 | 9,065 |
| Long-term deposits received | 5,337 | 5,363 |
| Other | 1,713 | 2,092 |
| Total noncurrent liabilities | 49,489 | 47,086 |
| Total liabilities | 107,311 | 102,553 |
| Net assets | | |
| Shareholders' equity | | |
| Capital stock | 13,226 | 13,226 |
| Capital surplus | 2,417 | 2,454 |
| Retained earnings | 124,788 | 128,564 |
| Treasury stock | (1,368) | (1,682) |
| Total shareholders' equity | 139,064 | 142,563 |
| Accumulated other comprehensive income | | |
| Valuation difference on available-for-sale securities | 9,814 | 7,125 |
| Deferred gains or losses on hedges | 114 | 84 |
| Foreign currency translation adjustment | (196) | (1,102) |
| Remeasurements of defined benefit plans | (599) | (908) |
| Total accumulated other comprehensive income | 9,133 | 5,199 |
| Noncontrolling interests | 31,597 | 33,566 |
| Total net assets | 179,795 | 181,329 |
| Total liabilities and net assets | 287,106 | 283,882 |

## (2) Consolidated Statements of Income and Consolidated Statements of Comprehensive Income

### (Consolidated Statements of Income)

(Millions of Yen)

| | FY2019 (Apr. 1, 2018 – Mar. 31, 2019) | FY2020 (Apr. 1, 2019 – Mar. 31, 2020) |
|---|---|---|
| Net sales | 277,443 | 281,191 |
| Cost of sales | 168,694 | 172,574 |
| Gross profit | 108,749 | 108,617 |
| Selling, general and administrative expenses | 90,945 | 92,781 |
| Operating income | 17,804 | 15,836 |
| Nonoperating income | | |
| Interest income | 234 | 309 |
| Dividends income | 565 | 601 |
| Other | 660 | 547 |
| Total nonoperating income | 1,461 | 1,458 |
| Nonoperating expenses | | |
| Interest expenses | 387 | 403 |
| Foreign exchange losses | 122 | 255 |
| Other | 396 | 366 |
| Total nonoperating expenses | 905 | 1,025 |
| Ordinary income | 18,359 | 16,269 |
| Extraordinary income | | |
| Gain on sales of investment securities | 21 | 1,130 |
| Gain on sale of businesses | 291 | - |
| Other | 383 | 342 |
| Total extraordinary income | 696 | 1,473 |
| Extraordinary loss | | |
| Loss on sales and retirement of non-current assets | 318 | 319 |
| Impairment loss | 696 | 880 |
| Loss on valuation of investment securities | 32 | 260 |
| Provision for environmental measures | - | 415 |
| Other | 350 | 223 |
| Total extraordinary losses | 1,397 | 2,099 |
| Income before income taxes and minority interests | 17,658 | 15,643 |
| Income taxes-current | 5,443 | 5,077 |
| Income taxes-deferred | (132) | (125) |
| Total income taxes | 5,310 | 4,952 |
| Net income | 12,347 | 10,691 |
| Net income attributable to the noncontrolling interest | 1,936 | 1,710 |
| Net income attributable to owners of the parent | 10,411 | 8,980 |

**(Consolidated Statements of Comprehensive Income)**

(Millions of Yen)

| | FY2019 (Apr. 1, 2018 – Mar. 31, 2019) | FY2020 (Apr. 1, 2019 – Mar. 31, 2020) |
|---|---|---|
| Net income | 12,347 | 10,691 |
| Other comprehensive income | | |
| Valuation difference on available-for-sale securities | (1,705) | (2,689) |
| Deferred gains or losses on hedges | 228 | (30) |
| Foreign currency translation adjustment | (3,646) | (1,160) |
| Remeasurements of defined benefit plans | 25 | (343) |
| Total other comprehensive income | (5,098) | (4,223) |
| Comprehensive income | 7,249 | 6,467 |
| (Comprehensive income attributable to) | | |
| Comprehensive income attributable to owners of the parent | 6,083 | 5,046 |
| Comprehensive income attributable to noncontrolling interest | 1,166 | 1,421 |

(3) Consolidated Statements of Change in Net Assets

FY2019 (Apr. 1, 2018– Mar. 31, 2019)

(Millions of Yen)

| | Shareholders' equity | | | | |
|---|---|---|---|---|---|
| | Capital stock | Capital surplus | Retained earnings | Treasury stock | Total shareholders' equity |
| Balance at the beginning of current period | 13,226 | 2,219 | 117,571 | (1,367) | 131,649 |
| Changes of items during the period | | | | | |
| Dividends from surplus | | | (3,194) | | (3,194) |
| Net income | | | 10,411 | | 10,411 |
| Purchase of treasury stock | | | | (0) | (0) |
| Disposal of treasury stock | | 0 | | 0 | 0 |
| Purchase of shares of consolidated subsidiaries | | 197 | | | 197 |
| Net changes of items other than shareholders' equity | | | | | |
| Total changes of items during the period | – | 197 | 7,217 | (0) | 7,414 |
| Balance at the end of current period | 13,226 | 2,417 | 124,788 | (1,368) | 139,064 |

| | Accumulated other comprehensive income | | | | | Minority interests | Total net assets |
|---|---|---|---|---|---|---|---|
| | Valuation difference on available-for-sale securities | Deferred gains or losses on hedges | Foreign currency translation adjustment | Remeasurements of defined benefit plans | Total accumulated other comprehensive income | | |
| Balance at the beginning of current period | 11,520 | (120) | 2,645 | (583) | 13,461 | 31,106 | 176,217 |
| Changes of items during the period | | | | | | | |
| Dividends from surplus | | | | | | | (3,194) |
| Net income | | | | | | | 10,411 |
| Purchase of treasury stock | | | | | | | (0) |
| Disposal of treasury stock | | | | | | | 0 |
| Purchase of shares of consolidated subsidiaries | | | | | | | 197 |
| Net changes of items other than shareholders' equity | (1,705) | 235 | (2,841) | (16) | (4,328) | 491 | (3,836) |
| Total changes of items during the period | (1,705) | 235 | (2,841) | (16) | (4,328) | 491 | 3,577 |
| Balance at the end of current period | 9,814 | 114 | (196) | (599) | 9,133 | 31,597 | 179,795 |

FY2020 (Apr. 1, 2019 – Mar. 31, 2020)

(Millions of Yen)

| | Shareholders' equity | | | | |
|---|---|---|---|---|---|
| | Capital stock | Capital surplus | Retained earnings | Treasury stock | Total shareholders' equity |
| Balance at the beginning of current period | 13,226 | 2,417 | 124,788 | (1,368) | 139,064 |
| Cumulative effects of changes in accounting policies | | | 75 | | 75 |
| Restated balance | 13,226 | 2,417 | 124,863 | (1,368) | 139,139 |
| Changes of items during the period | | | | | |
| Dividends from surplus | | | (3,593) | | (3,593) |
| Net income | | | 8,980 | | 8,980 |
| Purchase of treasury stock | | | | (2,000) | (2,000) |
| Retirement of treasury stock | | (1,686) | | 1,686 | — |
| Purchase of shares of consolidated subsidiaries | | 36 | | | 36 |
| Transfer to capital surplus from retained earnings | | 1,686 | (1,686) | | — |
| Net changes of items other than shareholders' equity | | | | | |
| Total changes of items during the period | — | 36 | 3,700 | (313) | 3,423 |
| Balance at the end of current period | 13,226 | 2,454 | 128,564 | (1,682) | 142,563 |

| | Accumulated other comprehensive income | | | | | Minority interests | Total net assets |
|---|---|---|---|---|---|---|---|
| | Valuation difference on available-for-sale securities | Deferred gains or losses on hedges | Foreign currency translation adjustment | Remeasurements of defined benefit plans | Total accumulated other comprehensive income | | |
| Balance at the beginning of current period | 9,814 | 114 | (196) | (599) | 9,133 | 31,597 | 179,795 |
| Cumulative effects of changes in accounting policies | | | | | | 48 | 123 |
| Restated balance | 9,814 | 114 | (196) | (599) | 9,133 | 31,645 | 179,918 |
| Changes of items during the period | | | | | | | |
| Dividends from surplus | | | | | | | (3,593) |
| Net income | | | | | | | 8,980 |
| Purchase of treasury stock | | | | | | | (2,000) |
| Retirement of treasury stock | | | | | | | — |
| Purchase of shares of consolidated subsidiaries | | | | | | | 36 |
| Transfer to capital surplus from retained earnings | | | | | | | — |
| Net changes of items other than shareholders' equity | (2,689) | (30) | (905) | (308) | (3,934) | 1,921 | (2,013) |
| Total changes of items during the period | (2,689) | (30) | (905) | (308) | (3,934) | 1,921 | 1,410 |
| Balance at the end of current period | 7,125 | 84 | (1,102) | (908) | 5,199 | 33,566 | 181,329 |

**(4) Consolidated Statements of Cash Flows**

(Millions of Yen)

| | FY2019 (Apr. 1, 2018 – Mar. 31, 2019) | FY2020 (Apr. 1, 2019 – Mar. 31, 2020) |
|---|---|---|
| Net cash provided by (used in) operating activities | | |
| Income before income taxes and minority interests | 17,658 | 15,643 |
| Depreciation and amortization | 6,490 | 7,626 |
| Impairment loss | 696 | 880 |
| Amortization of goodwill | 865 | 847 |
| Increase (decrease) in provision for environmental measures | (2) | 408 |
| Interest and dividends income | (800) | (911) |
| Interest expenses | 387 | 403 |
| Loss (gain) on sales and retirement of non-current assets | 27 | 268 |
| Loss (gain) on sales of investment securities | (21) | (1,128) |
| Loss (gain) on sale of businesses | (291) | - |
| Loss (gain) on valuation of investment securities | 32 | 260 |
| Decrease (increase) in notes and accounts receivable-trade | (2,900) | (1,291) |
| Decrease (increase) in inventories | (5,060) | (3,159) |
| Increase (decrease) in notes and accounts payable-trade | 324 | (340) |
| Increase (decrease) in liquor taxes payable | 946 | (2,534) |
| Increase (decrease) in accrued consumption taxes | 244 | (994) |
| Increase (decrease) in other current liabilities | 868 | (595) |
| Other, net | 241 | 802 |
| Subtotal | 19,708 | 16,188 |
| Interest and dividends income received | 782 | 917 |
| Interest expenses paid | (396) | (405) |
| Income taxes paid | (6,586) | (4,955) |
| Net cash provided by (used in) operating activities | 13,508 | 11,744 |
| Net cash provided by (used in) investing activities | | |
| Payments into time deposits | (15,310) | (6,785) |
| Proceeds from withdrawal of time deposits | 14,846 | 10,564 |
| Purchase of securities | (11,467) | (8,478) |
| Proceeds from sales and redemption of securities | 12,528 | 11,507 |
| Purchase of property, plant and equipment and intangible assets | (10,671) | (12,121) |
| Proceeds from sales of investment securities | 33 | 1,636 |
| Proceeds from purchase of shares of subsidiaries resulting in change in scope of consolidation | - | 350 |
| Purchase of shares of subsidiaries resulting in change in scope of consolidation | (53) | - |
| Proceeds from transfer of businesses | 1,067 | - |
| Other, net | (187) | (365) |
| Net cash provided by (used in) investing activities | (9,213) | (3,690) |
| Net cash provided by (used in) financing activities | | |
| Repayments of long-term loans payable | (304) | (5,160) |
| Purchase of treasury shares | (0) | (2,000) |
| Cash dividends paid | (3,191) | (3,589) |
| Repayments of lease obligations | (219) | (641) |
| Payments from changes in ownership interests in subsidiaries that do not result in change in scope of consolidation | (203) | - |
| Other, net | (323) | (262) |
| Net cash provided by (used in) financing activities | (4,243) | (11,653) |
| Effect of exchange rate change on cash and cash equivalents | (812) | (439) |
| Net increase (decrease) in cash and cash equivalent | (760) | (4,039) |
| Cash and cash equivalents at beginning of period | 49,341 | 48,580 |
| Cash and cash equivalents at end of period | 48,580 | 44,541 |

**(5) Notes to Consolidated Financial Statements**

**(Notes on Premise of Going Concern)**

No items to report.

**(Changes in Accounting Policies)**

Overseas subsidiaries that apply U.S. GAAP adopted ASU No. 2014-09 Revenue from Contracts with Customers ("ASU No. 2014-09") effective from the beginning of the fiscal year ended March 31, 2020. The method of recognizing the cumulative impact due to the adoption of the standard on the commencement date of adoption, which is permitted as an interim measure, was employed for the adoption of ASU No. 2014-09.

Accompanying this, revenue is recognized at the time of transfer to the customer of the promised goods or services in an amount that reflects the consideration that the entity expects to be entitled to in exchange for those goods and services.

The impact on the Consolidated Financial Statements from the adoption of this accounting standard is immaterial.

Overseas subsidiaries that apply International Financial Reporting Standards (IFRS) adopted IFRS 16 Leases ("IFRS 16") effective from the beginning of the fiscal year ended March 31, 2020. The method of recognizing the cumulative impact due to the adoption of the standard on the commencement date of adoption, which is permitted as an interim measure, was employed for the adoption of IFRS 16.

Accompanying this, as a rule, the lessee recognizes all leases as assets and liabilities on the commencement date of adoption.

The impact on the Consolidated Financial Statements from the adoption of this accounting standard is immaterial.

**(Segment Information)**

1. Overview of Reported Segments

Reporting segments are the segments of the Takara Group for which financial information can be obtained. The Board of Directors, top organization for decision making on Group management, examines such information to determine the allocation of management resources and evaluate the business performance on a regular basis.

The Group consists of the corporate groups centered on the operating companies Takara Shuzo Co., Ltd., Takara Shuzo International Co., Ltd. and Takara Bio Inc.; other businesses; and the Company, which manages the whole group as the holding company. All operating companies develop comprehensive business strategies, covering both domestic and overseas operations, for the goods, products and services that they offer, and work to expand their business operations. Accordingly, the Group has defined three reported segments based on the content of goods, products and services, while taking into consideration the scope of managerial responsibility and the capacity to evaluate business performance. These three reported segments are Takara Shuzo, the Takara Shuzo International Group, and the Takara Bio Group.

Takara Shuzo primarily engages in the manufacture and sale of alcoholic beverages and seasonings in Japan. The Takara Shuzo International Group engages in the export of alcoholic beverages from Japan, the manufacture and sale of alcoholic beverages at overseas locations, and the Japanese Food Wholesale Business in overseas markets. The Takara Bio Group engages in the manufacture and sale of products such as research reagents and scientific instruments as well as contract research services and research and development of gene and cell therapies.

2. Calculation method for net sales, income or loss, assets, and other items of each reported segment

The accounting treatment of reported business segments is generally the same as that explained in "Basis of Presentation of Consolidated Financial Statements."

The figures for the income of reported segments are based on operating income. Intersegment income is based on the prevailing market price.

3. Net sales, Income (Loss), Assets and Other items by Reported Segment

Previous Fiscal Year (From April 1, 2018, to March 31, 2019)

(Millions of yen)

| | Reported Segment | | | | Other (Note: 1) | Total | Adjustment (Note: 2) | Amount recognized in consolidated financial statements (Note: 3) |
|---|---|---|---|---|---|---|---|---|
| | Takara Shuzo | Takara Shuzo International Group | Takara Bio Group | Subtotal | | | | |
| Net sales | | | | | | | | |
| External customers | 151,805 | 77,573 | 35,432 | 264,811 | 12,627 | 277,439 | 3 | 277,443 |
| Intersegment | 651 | 261 | 408 | 1,321 | 20,114 | 21,435 | (21,435) | — |
| Total | 152,457 | 77,834 | 35,841 | 266,132 | 32,742 | 298,875 | (21,431) | 277,443 |
| Segment income (loss) | 5,948 | 4,532 | 5,463 | 15,944 | 1,954 | 17,899 | (95) | 17,804 |
| Segment assets | 92,682 | 68,003 | 71,040 | 231,726 | 19,315 | 251,041 | 36,064 | 287,106 |
| Other items | | | | | | | | |
| Depreciation and amortization | 2,248 | 1,013 | 2,691 | 5,953 | 219 | 6,172 | 317 | 6,490 |
| Amortization of goodwill | — | 362 | 502 | 865 | — | 865 | — | 865 |
| Investment in equity-method affiliates | — | — | — | — | — | — | 1,526 | 1,526 |
| Increase in total fixed assets, property, plant and equipment and intangible assets | 3,128 | 1,162 | 6,002 | 10,293 | 230 | 10,523 | 148 | 10,671 |

Notes: 1. Other includes business segments that are not part of reported segments, such as the real estate rental business and the transportation business of domestic Group companies among others.

2. Details of adjustment amounts are as follows.

(1) Net sales to external customers are income from business contracting recorded at the Company.

(2) Segment income (loss) comprises intersegment eliminations of ¥99 million and loss of the Company not allocated to business segments of ¥194 million.

(3) Segment assets include assets of the Company not allocated to business segments of ¥59,694 million and other adjustment (principally intersegment eliminations) of ¥(23,629) million. Assets attributed to the Company include surplus funds and long-term investment assets.

(4) Depreciation and amortization primarily comprises depreciation and amortization recognized by the Company.

(5) Investment in equity-method affiliates comprises investments in equity-method affiliates not allocated to business segments.

(6) Increase in total fixed assets, property, plant and equipment and intangible assets comprises increases recognized by the Company.

3. Segment income (loss) has been adjusted to the operating income of consolidated financial statements.

Fiscal Year under Review (From April 1, 2019, to March 31, 2020)

(Millions of yen)

| | Reported Segment | | | | Other (Note: 1) | Total | Adjustment (Note: 2) | Amount recognized in consolidated financial statements (Note: 3) |
|---|---|---|---|---|---|---|---|---|
| | Takara Shuzo | Takara Shuzo International Group | Takara Bio Group | Subtotal | | | | |
| Net sales | | | | | | | | |
| External customers | 152,496 | 82,456 | 34,563 | 269,516 | 11,670 | 281,186 | 5 | 281,191 |
| Intersegment | 644 | 309 | 1 | 955 | 20,131 | 21,087 | (21,087) | — |
| Total | 153,141 | 82,765 | 34,565 | 270,472 | 31,801 | 302,273 | (21,082) | 281,191 |
| Segment income (loss) | 4,175 | 3,532 | 6,274 | 13,982 | 2,018 | 16,001 | (164) | 15,836 |
| Segment assets | 93,083 | 75,183 | 75,009 | 243,276 | 19,577 | 262,853 | 21,028 | 283,882 |
| Other items | | | | | | | | |
| Depreciation and amortization | 2,736 | 1,434 | 2,921 | 7,093 | 216 | 7,309 | 317 | 7,626 |
| Amortization of goodwill | — | 350 | 496 | 847 | — | 847 | — | 847 |
| Investment in equity-method affiliates | — | — | — | — | — | — | 1,608 | 1,608 |
| Increase in total fixed assets, property, plant and equipment and intangible assets | 5,520 | 2,696 | 5,365 | 13,582 | 219 | 13,802 | 393 | 14,195 |

Notes: 1. Other includes business segments that are not part of reported segments, such as the real estate rental business and the transportation business of domestic Group companies among others.

2 Details of adjustment amounts are as follows.

(1) Net sales to external customers are income from business contracting recorded at the Company.

(2) Segment income (loss) comprises intersegment eliminations of ¥57 million and loss of the Company not allocated to business segments of ¥222 million.

(3) Segment assets include assets of the Company not allocated to business segments of ¥51,819 million and other adjustment (principally intersegment eliminations) of ¥(30,791) million. Assets attributed to the Company include surplus funds and long-term investment assets.

(4) Depreciation and amortization primarily comprises depreciation and amortization recognized by the Company.

(5) Investment in equity-method affiliates comprises investments in equity-method affiliates not allocated to business segments.

(6) Increase in total fixed assets, property, plant and equipment and intangible assets comprises increases of the Company not allocated to business segments of ¥493 million and intersegment eliminations of ¥(99) million.

3. Segment income (loss) has been adjusted to the operating income of consolidated financial statements.

4. Information on Impairment Loss on Fixed Assets by Reportable Segment

Previous Fiscal Year (From April 1, 2018, to March 31, 2019)

(Millions of yen)

| | Takara Shuzo | Takara Shuzo International Group | Takara Bio Group | Other | Intersegment eliminations | Total |
|---|---|---|---|---|---|---|
| Impairment loss | — | — | 696 | — | — | 696 |

Fiscal Year under Review (From April 1, 2019, to March 31, 2020)

(Millions of yen)

| | Takara Shuzo | Takara Shuzo International Group | Takara Bio Group | Other | Intersegment eliminations | Total |
|---|---|---|---|---|---|---|
| Impairment loss | — | — | 880 | — | — | 880 |

**(Per Share Information)**

| | Previous Fiscal Year (From April 1, 2018, to March 31, 2019) | Fiscal Year under Review (From April 1, 2019, to March 31, 2020) |
|---|---|---|
| Net assets per share | ¥742.36 | ¥747.39 |
| Profit per share | ¥52.15 | ¥45.11 |

Notes 1. Fully diluted profit per share is not presented since there were no potential shares.

2. The basis of calculation of net assets per share is as follows.

| | Previous Fiscal Year (As of March 31, 2019) | Fiscal Year under Review (As of March 31, 2020) |
|---|---|---|
| Total net assets (¥ million) | 179,795 | 181,329 |
| Amount deducted from total net assets (¥ million) | 31,597 | 33,566 |
| (of which minority interests) (¥ million) | (31,597) | (33,566) |
| Net assets at term-end related to shares of common stock (¥ million) | 148,197 | 147,762 |
| Shares of common stock at term-end used to calculate net assets per share (1,000 shares) | 199,630 | 197,704 |

3. The basis of calculation of net income per share and fully diluted net income per share is as follows.

| | Previous Fiscal Year (From April 1, 2018, to March 31, 2019) | Fiscal Year under Review (From April 1, 2019, to March 31, 2020) |
|---|---|---|
| Net income attributable to owners of the parent (¥ million) | 10,411 | 8,980 |
| Amount not belonging to common shareholders (¥ million) | — | — |
| Net income related to shares of common stock (¥ million) | 10,411 | 8,980 |
| Average number of shares outstanding during the term (1,000 shares) | 199,630 | 199,062 |

**(Significant Subsequent Events)**

(Significant Facility investment)

Takara Bio Inc., a consolidated subsidiary of the Company, has resolved a facility investment in Takara Bio USA, Inc. (TBUSA), its consolidated subsidiary company at the board of directors' meeting held on January 23, 2020, and completed the acquisition of the land and building on May 11 (U.S. time).

1. Reason for facility investment
   The reason is that TBUSA utilizes as a new facility. Also, TBUSA plans for relocation at the time of terminating the agreement of the current lease set in August 2021.

2. Outline of facility investment

| | |
|---|---|
| (1) Location | San Jose, California, USA |
| (2) Purpose | Land, building and interior construction located newly |
| (3) Investment amount | About 76 million U.S. dollars |

3. Installation time of equipment

| | |
|---|---|
| May 2020 | Completed the acquisition of land and building |
| 2021 | Planned for completion of interior construction |
| 2021 | Planned for relocation |

4. Significant impact on marketing and productivity
   The impact of this acquisition on the consolidated results for the fiscal year ending March 31, 2021 is immaterial.

(Conclusion of Significant Agreement)

Takara Bio Inc. (hereinafter "Takara Bio"), a consolidated subsidiary of the Company, concluded a licensing agreement with Tasly Biopharmaceuticals Co., Ltd. (head office: Shanghai, China; hereinafter "Tasly") as of May 11, 2020 to license exclusive development, manufacturing, and sales of the oncolytic virus canerpaturev (C-REV) in China.

Based on this agreement, Takara Bio will transfer the manufacturing technologies for C-REV to Tasly and provide development information. Meanwhile, Tasly will advance clinical development with the aim of launching C-REV in the market within China (including Hong Kong and Macau but excluding Taiwan) as a new anticancer drug.

In addition, in conjunction with the conclusion of this agreement, Takara Bio will receive upfront, annual and milestone payments, according to the development progress. After the market launch, Takara Bio will receive running royalties according to sales, in addition to milestone payments when the sales target is achieved.

# 2020年3月期
# 決算短信補足資料

Supplement for the Consolidated Financial Statements
for the Year Ended March 31, 2020


1. 宝ホールディングス(連結)
Takara Holdings Inc. -Consolidated-
   ① グループ別要約損益計算書
   Consolidated Statements of Income by Business Group (Summary)
   ② 要約貸借対照表
   Consolidated Balance Sheets (Summary)
2. 宝酒造
Takara Shuzo
   要約損益計算書
   Statements of Income (Summary)
3. 宝酒造インターナショナルグループ
Takara Shuzo International Group
   要約損益計算書
   Statements of Income (Summary)
4. タカラバイオグループ
Takara Bio Group
   要約損益計算書
   Statements of Income (Summary)
5. 6年間の財務サマリー(グループ別)
Six-Year Financial Summary by Business Group
6. 2020年3月期　参考資料
Reference Data for the Year Ended March 31, 2020
7. 2021年3月期 業績予想
Financial forecast for the year ending March 31, 2021
   ① 宝ホールディングス(連結)
   Takara Holdings Inc. -Consolidated-
   ② 宝酒造
   Takara Shuzo
   ③ 宝酒造インターナショナルグループ
   Takara Shuzo International Group
   ④ タカラバイオグループ
   Takara Bio Group
8. 2021年3月期　参考資料
Reference Data for the year ending March 31, 2021



宝ホールディングス株式会社
TAKARA HOLDINGS INC.
財務・IR部　Financial & Investor Relations Dept.
TEL 075(241)5124
FAX 075(241)5127
E-Mail ir@takara.co.jp

## 将来見通しに関する注意事項

この資料中の当社および当社グループの現在の計画、見通し、戦略、確信などのうち、歴史的事実でないものは、将来の業績に関する見通しであり、これらは現時点において入手可能な情報から得られた当社経営陣の判断に基づくものですが、重大なリスクや不確実性を含んでいる情報から得られた多くの仮定および考えに基づきなされたものであります。実際の業績は、さまざまな要素によりこれら予測とは大きく異なる結果となり得ることをご承知おきください。

実際の業績に影響を与える要素には、経済情勢、特に消費動向、為替レートの変動、法律・行政制度の変化、競合会社の価格・製品戦略による圧力、当社の既存製品および新製品の販売力の低下、生産中断、当社の知的所有権に対する侵害、急速な技術革新、重大な訴訟における不利な判決等がありますが、業績に影響を与える要素はこれらに限定されるものではありません。

**Forward-Looking Statements**

Statements in this document, other than those based on historical fact, concerning the current plans, prospects, strategies and expectations of the Company and its Group represent forecasts of future results. While such statements are based on the conclusions of management according to information available at the time of writing, they reflect many assumptions and opinions derived from information that includes major risks and uncertainties. Actual results may vary significantly from these forecasts due to various factors.

Factors that could influence actual results include, but are not limited to, economic conditions, especially trends in consumer spending, as well as exchange rate fluctuations, changes in laws and government systems, pressure from competitors' prices and product strategies, declines in selling power of the Company's existing and new products, disruptions to production, violations of the Company's intellectual property rights, rapid advances in technology and unfavorable verdicts in major litigation.

宝ホールディングス株式会社　財務・IR部
Takara Holdings Inc.  Financial & Investor Relations Dept.

TEL 075(241)5124　FAX 075(241)5127
E-Mail ir@takara.co.jp

## 1. 宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

### ① グループ別要約損益計算書 :Consolidated Statements of Income by Business Group (Summary)

(百万円 :Millions of Yen)

| | 2019年3月期 FY2019 | 2020年3月期 FY2020 / Apr. 1, 2019 - Mar. 31, 2020 | | 対前期 Change from FY2019 | | 対2/13予想 Change from forecast anounced Feb. 2020 | |
|---|---|---|---|---|---|---|---|
| | 実績 Actual (a) | 2/13予想 Forecast announced Feb. 13, 2020 (b) | 実績 Actual (c) | 増減 Change (c-a) | 比 % (c/a) | 増減 Difference (c-b) | 比 % (c/b) |
| 宝酒造 Takara Shuzo | 152,457 | 153,074 | 153,141 | 683 | 100.4% | 67 | 100.0% |
| 宝酒造インターナショナルグループ Takara Shuzo International Group | 77,834 | 82,219 | 82,765 | 4,931 | 106.3% | 546 | 100.7% |
| タカラバイオ グループ Takara Bio Group | 35,841 | 34,300 | 34,565 | △ 1,275 | 96.4% | 265 | 100.8% |
| その他 Other | 32,742 | 31,748 | 31,801 | △ 940 | 97.1% | 53 | 100.2% |
| 調整額 Adjustment | △ 21,431 | △ 21,341 | △ 21,082 | 349 | ― | 258 | ― |
| 売上高 Net sales | 277,443 | 280,000 | 281,191 | 3,748 | 101.4% | 1,191 | 100.4% |
| 売上原価 Cost of sales | 168,694 | 171,500 | 172,574 | 3,880 | 102.3% | 1,074 | 100.6% |
| 売上総利益 Gross profit | 108,749 | 108,500 | 108,617 | △ 132 | 99.9% | 117 | 100.1% |
| 運送費、保管料 Transportation and storage | 10,162 | 10,900 | 11,000 | 837 | 108.2% | 100 | 100.9% |
| 広告宣伝費 Advertising | 2,755 | 2,000 | 2,051 | △ 704 | 74.4% | 51 | 102.6% |
| 販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p. | 34,012 | 35,400 | 35,073 | 1,060 | 103.1% | △ 326 | 99.1% |
| 研究開発費 Research and development | 4,708 | 4,400 | 4,259 | △ 449 | 90.5% | △ 140 | 96.8% |
| 管理費、その他 Other, net | 39,305 | 40,500 | 40,395 | 1,090 | 102.8% | △ 104 | 99.7% |
| 販売費及び一般管理費 SG&A expenses | 90,945 | 93,200 | 92,781 | 1,835 | 102.0% | △ 418 | 99.6% |
| 宝酒造 Takara Shuzo | 5,948 | 3,848 | 4,175 | △ 1,772 | 70.2% | 327 | 108.5% |
| 宝酒造インターナショナルグループ Takara Shuzo International Group | 4,532 | 3,576 | 3,532 | △ 1,000 | 77.9% | △ 43 | 98.8% |
| タカラバイオ グループ Takara Bio Group | 5,463 | 6,200 | 6,274 | 811 | 114.8% | 74 | 101.2% |
| その他 Other | 1,954 | 2,035 | 2,018 | 64 | 103.3% | △ 16 | 99.2% |
| 調整額 Adjustment | △ 95 | △ 359 | △ 164 | △ 69 | ― | 194 | ― |
| 営業利益(△:損失) Operating income(Δ:loss) | 17,804 | 15,300 | 15,836 | △ 1,967 | 88.9% | 536 | 103.5% |
| 受取利息・配当金 Interest and Dividends income | 800 | 800 | 911 | 110 | 113.9% | 111 | 113.9% |
| その他営業外収益 Other, net | 660 | 600 | 547 | △ 113 | 82.8% | △ 52 | 91.2% |
| 営業外収益 Non-operating income | 1,461 | 1,400 | 1,458 | △ 2 | 99.8% | 58 | 104.2% |
| 支払利息 Interest and discounts expenses | 387 | 400 | 403 | 16 | 104.3% | 3 | 101.0% |
| その他営業外費用 Other, net | 518 | 600 | 621 | 102 | 119.9% | 21 | 103.6% |
| 営業外費用 Non-operating expenses | 905 | 1,000 | 1,025 | 119 | 113.2% | 25 | 102.5% |
| 経常利益(△:損失) Ordinary income(Δ:loss) | 18,359 | 15,700 | 16,269 | △ 2,089 | 88.6% | 569 | 103.6% |
| 特別利益 Extraordinary income | 696 | 1,200 | 1,473 | 776 | 211.5% | 273 | 122.8% |
| 特別損失 Extraordinary loss | 1,397 | 1,500 | 2,099 | 701 | 150.2% | 599 | 140.0% |
| 税金等調整前当期純利益(△:損失) Income before income taxes(Δ:loss) | 17,658 | 15,400 | 15,643 | △ 2,014 | 88.6% | 243 | 101.6% |
| 法人税、住民税及び事業税 Current income taxes | 5,443 | 5,200 | 5,077 | △ 365 | 93.3% | △ 247 | 95.2% |
| 法人税等調整額 Deferred income taxes | △ 132 | | △ 125 | 7 | ― | | |
| 当期純利益(△:損失) Net income(Δ:loss) | 12,347 | 10,200 | 10,691 | △ 1,656 | 86.6% | 491 | 104.8% |
| 非支配株主に帰属する当期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss) | 1,936 | 1,600 | 1,710 | △ 225 | 88.4% | 110 | 106.9% |
| 親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent(Δ:loss) | 10,411 | 8,600 | 8,980 | △ 1,430 | 86.3% | 380 | 104.4% |
| 設備投資額(有形・無形) Capital expenditures | 10,671 | 15,670 | 14,195 | 3,524 | 133.0% | △ 1,474 | 90.6% |
| 減価償却費(有形・無形) Depreciation and Amortization | 6,490 | 7,350 | 7,626 | 1,136 | 117.5% | 276 | 103.8% |
| のれん償却額 Amortization of goodwill | 865 | 830 | 847 | △ 18 | 97.9% | 17 | 102.1% |

| | |
|---|---|
| 営業外収益 Non-operating income | 受取利息 309、受取配当金 601 など Interest income 309, Dividends income 601, etc. |
| 営業外費用 Non-operating expenses | 支払利息 235、社債利息 167、為替差損 255 など Interest expense 235, Interest on bonds 167, Foreign exchange losses 255 etc. |
| 特別利益 Extraordinary income | 投資有価証券売却益 1,130 など Gain on sales of investment securities 1,130 etc. |
| 特別損失 Extraordinary loss | 固定資産除売却損 319、減損損失 880 など Loss on sales and retirement of non-current assets 319, Impairment loss 880 etc. |

② 要約貸借対照表 :Consolidated Balance Sheets (Summary)

**資産の部** :Assets　　（百万円 :Millions of Yen）

| | 2019年3月期末 As of Mar. 31, 2019 | 2020年3月期末 As of Mar. 31, 2020 | 増減 Change | 主な増減理由 Reference |
|---|---|---|---|---|
| (流動資産) (Total current assets) | 175,011 | 168,820 | △ 6,191 | （億円 :One hundred millions of Yen） |
| 現金及び預金 Cash and deposits | 49,415 | 47,265 | △ 2,150 | 宝HLD △22.3、宝酒造△18.0 Takara Holdings △22.3, Takara Shuzo △18.0 |
| 受取手形及び売掛金 Notes and accounts receivable-trade | 59,780 | 61,017 | 1,237 | |
| 有価証券 Marketable securities | 16,089 | 7,352 | △ 8,736 | 宝HLD △85.0 Takara Holdings △85.0 |
| たな卸資産 Inventories | 46,035 | 48,976 | 2,941 | |
| その他 Other current assets | 4,006 | 4,515 | 509 | |
| 貸倒引当金 Allowance for doubtful accounts | △ 315 | △ 307 | 8 | |
| (固定資産) (Total fixed assets) | 112,094 | 115,061 | 2,966 | |
| 〔有形固定資産〕 [Property, plant and equipment] | 60,576 | 69,835 | 9,258 | |
| 建物及び構築物 Buildings and structures | 18,706 | 24,148 | 5,441 | （当期の有形・無形固定資産の増減内訳） Reference of Property, plant and equipment and Intangible assets |
| 機械装置及び運搬具 Machinery, equipment and vehicles | 12,259 | 16,670 | 4,411 | 新規取得 ＋141.9 （TS＋55.2、TSI＋26.9、TB＋53.6） Newly purchases +141.9 |
| 土地 Land | 18,559 | 18,337 | △ 221 | 減価償却 △76.2 （TS△27.3、TSI△14.3、TB△29.2） Depreciation Δ76.2 |
| その他 Other property, plant and equipment | 11,051 | 10,679 | △ 372 | その他増減 +14.7 Other, net +14.7 |
| 〔無形固定資産〕 [Intangible fixed assets] | 19,914 | 18,700 | △ 1,214 | |
| のれん Goodwill | 12,400 | 11,750 | △ 650 | |
| その他 Other intangible fixed assets | 7,514 | 6,950 | △ 563 | |
| 〔投資その他の資産〕 [Investments and other assets] | 31,603 | 26,525 | △ 5,077 | |
| 投資有価証券 Investment securities | 26,143 | 21,720 | △ 4,422 | 宝HLD △42.3 Takara Holdings △42.3 |
| その他 Other assets | 5,520 | 4,873 | △ 646 | |
| 貸倒引当金 Allowance for doubtful accounts | △ 60 | △ 69 | △ 8 | |
| 資産合計 Total assets | 287,106 | 283,882 | △ 3,224 | |

(TH=Takara Holdings Inc., TS=Takara Shuzo TSI=Takara Shuzo International Group, TB=Takara Bio Group)

② 要約貸借対照表 :Consolidated Balance Sheets (Summary)

**負債及び純資産 の部** :Liabilities and net assets （百万円 :Millions of Yen）

| | 2019年3月期末 As of Mar. 31, 2019 | 2020年3月期末 As of Mar. 31, 2020 | 増減 Change | 主な増減理由 Reference |
|---|---|---|---|---|
| (流動負債) (Total current liabilities) | 57,822 | 55,466 | △ 2,355 | （億円 :One hundred millions of Yen） |
| 支払手形及び買掛金 Notes and accounts payable-trade | 16,374 | 16,440 | 65 | |
| 短期借入金 Short-term loans payable | 9,960 | 4,787 | △ 5,173 | 宝HLD△51.6 Takara Holdings △51.6 |
| 1年内償還予定の社債 Current portion of bonds | ― | 5,000 | 5,000 | 宝HLD＋50.0(第11回普通社債 2020年5月償還) Takara Holdings ＋50.0(#11SB Redemption May.2020) |
| 未払酒税 Accrued alcohol tax | 10,224 | 7,690 | △ 2,534 | |
| 未払費用 Accrued expenses | 5,809 | 5,511 | △ 298 | |
| 販売促進引当金 Reserve for sales promotion expenses | 1,921 | 2,094 | 173 | |
| その他 Other current liabilities | 13,531 | 13,942 | 411 | |
| (固定負債) (Total non-current liabilities) | 49,489 | 47,086 | △ 2,402 | |
| 社債 Bonds payable | 25,000 | 20,000 | △ 5,000 | 宝HLD△50.0(第11回普通社債 2020年5月償還) Takara Holdings △50.0(#11SB Redemption May.2020) |
| 長期借入金 Long-term loans payable | 5,415 | 5,448 | 32 | |
| 退職給付に係る負債 Net defined benefit liability | 8,757 | 9,065 | 307 | |
| 預り金 Deposits from customers | 5,337 | 5,363 | 25 | |
| その他 Other non-current liabilities | 4,977 | 7,209 | 2,231 | |
| 負債合計 Total liabilities | 107,311 | 102,553 | △ 4,758 | |
| 資本金 Capital stock | 13,226 | 13,226 | ― | |
| 資本剰余金 Capital surplus | 2,417 | 2,454 | 36 | |
| 利益剰余金 Retained earnings | 124,788 | 128,564 | 3,776 | |
| 自己株式 Treasury stock | △ 1,368 | △ 1,682 | △ 313 | |
| (株主資本) (Total owner's equity) | 139,064 | 142,563 | 3,499 | |
| その他有価証券評価差額金 Valuation difference on available-for-sale securities | 9,814 | 7,125 | △ 2,689 | |
| 繰延ヘッジ損益 Deffered gains or losses on hedges | 114 | 84 | △ 30 | |
| 為替換算調整勘定 Translation adjustments | △ 196 | △ 1,102 | △ 905 | TSI △5.8、TB △3.2 USD=109.55JPY, EUR=122.51JPY, GBP=143.48JPY (Dec. 2019) USD=110.91JPY, EUR=126.88JPY, GBP=140.35JPY (Dec. 2018) |
| 退職給付に係る調整累計額 Remeasurements of defined benefit plans | △ 599 | △ 908 | △ 308 | |
| (その他の包括利益累計額) (Total valuation and translation adjustments) | 9,133 | 5,199 | △ 3,934 | |
| (非支配株主持分) (Noncontrolling interests) | 31,597 | 33,566 | 1,969 | |
| 純資産合計 Total net assets | 179,795 | 181,329 | 1,534 | |
| 負債純資産合計 Total liabilities and net assets | 287,106 | 283,882 | △ 3,224 | |

(TH=Takara Holdings Inc., TS=Takara Shuzo TSI=Takara Shuzo International Group, TB=Takara Bio Group)

## 2. 宝酒造 :Takara Shuzo

要約損益計算書 :Statements of Income (Summary)

（百万円 :Millions of Yen）

| | 2019年3月期 FY2019 | 2020年3月期 FY2020 / Apr. 1, 2019 - Mar. 31, 2020 | 対前期 Change from FY2019 | |
|---|---|---|---|---|
| | 実績 Actual (a) | 実績 Actual (c) | 増減 Change (c-a) | 比 % (c/a) |
| 焼酎 Shochu | 53,382 | 49,728 | △ 3,653 | 93.2% |
| 清酒 Sake | 21,394 | 20,488 | △ 906 | 95.8% |
| ソフトアルコール飲料 Light-alcohol refreshers | 38,777 | 43,023 | 4,245 | 110.9% |
| その他酒類 Other liquors | 6,482 | 6,405 | △ 77 | 98.8% |
| 本みりん Hon Mirin | 13,869 | 13,980 | 111 | 100.8% |
| その他調味料 Other seasonings | 9,714 | 10,330 | 616 | 106.3% |
| 原料用アルコール等 Raw alcohol | 8,836 | 9,183 | 347 | 103.9% |
| 売上高 Net sales | 152,457 | 153,141 | 683 | 100.4% |
| 売上原価 Cost of sales | 91,441 | 92,822 | 1,380 | 101.5% |
| 売上総利益 Gross profit | 61,015 | 60,318 | △ 697 | 98.9% |
| 運送費、保管料 Transportation and storage | 7,613 | 8,142 | 529 | 107.0% |
| 広告宣伝費 Advertising | 2,394 | 1,882 | △ 512 | 78.6% |
| 販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p. | 32,658 | 33,844 | 1,186 | 103.6% |
| 研究開発費 Research and development | 368 | 382 | 14 | 104.0% |
| 管理費、その他 Other, net | 12,032 | 11,890 | △ 141 | 98.8% |
| 販売費及び一般管理費 SG&A expenses | 55,067 | 56,142 | 1,075 | 102.0% |
| 営業利益（△：損失） Operating income(Δ:loss) | 5,948 | 4,175 | △ 1,772 | 70.2% |
| 営業外収益 Non-operating income | 764 | 236 | △ 527 | 31.0% |
| 営業外費用 Non-operating expenses | 232 | 299 | 66 | 128.4% |
| 経常利益（△：損失） Ordinary income(Δ:loss) | 6,480 | 4,113 | △ 2,367 | 63.5% |
| 特別利益 Extraordinary gain | 172 | 299 | 127 | 174.4% |
| 特別損失 Extraordinary loss | 348 | 564 | 216 | 162.2% |
| 税金等調整前当期純利益（△：損失） Income before income taxes(Δ:loss) | 6,304 | 3,848 | △ 2,455 | 61.0% |
| 法人税、住民税及び事業税 Current income taxes | 1,854 | 1,343 | △ 511 | 72.4% |
| 法人税等調整額 Deferred income taxes | 46 | △ 27 | △ 74 | ― |
| 当期純利益（△：損失） Net income(Δ:loss) | 4,402 | 2,532 | △ 1,869 | 57.5% |
| 設備投資額（有形・無形） Capital expenditures | 3,128 | 5,520 | 2,391 | 176.5% |
| 減価償却費（有形・無形） Depreciation and Amortization | 2,248 | 2,736 | 487 | 121.7% |

## 3. 宝酒造インターナショナルグループ :Takara Shuzo International Group

### 要約損益計算書 :Statements of Income (Summary)

（百万円 :Millions of Yen）

| | 2019年3月期 FY2019 | 2020年3月期 FY2020 / Apr. 1, 2019 - Mar. 31, 2020 | 対前期 Change from FY2019 | |
|---|---|---|---|---|
| | 実績 Actual (a) | 実績 Actual (c) | 増減 Change (c-a) | 比 % (c/a) |
| 海外酒類事業 Overseas Alcoholic beverages business | 10,758 | 11,365 | 607 | 105.6% |
| 海外日本食材卸事業 Japanese food wholesale business in overseas markets | 68,954 | 73,371 | 4,417 | 106.4% |
| その他 Other | 62 | 204 | 142 | 326.8% |
| 連結消去 Elimination | △ 1,940 | △ 2,175 | △ 235 | ― |
| 売上高 Net sales | 77,834 | 82,765 | 4,931 | 106.3% |
| 売上原価 Cost of sales | 54,823 | 58,882 | 4,058 | 107.4% |
| 売上総利益 Gross profit | 23,010 | 23,883 | 872 | 103.8% |
| 運送費、保管料 Transportation and storage | 2,277 | 2,656 | 379 | 116.7% |
| 広告宣伝費 Advertising | 110 | 84 | △ 26 | 76.2% |
| 販売促進費 Sales promotion | 734 | 756 | 21 | 103.0% |
| 管理費、その他 Other, net | 15,356 | 16,854 | 1,497 | 109.8% |
| 販売費及び一般管理費 SG&A expenses | 18,478 | 20,351 | 1,872 | 110.1% |
| 海外酒類事業 Overseas Alcoholic beverages business | 1,982 | 2,339 | 356 | 118.0% |
| 海外日本食材卸事業 Japanese food wholesale business in overseas markets | 3,921 | 2,735 | △ 1,186 | 69.8% |
| その他 Other | △ 935 | △ 853 | 82 | ― |
| 連結消去 Elimination | △ 436 | △ 689 | △ 252 | ― |
| 営業利益（△：損失） Operating income(Δ:loss) | 4,532 | 3,532 | △ 1,000 | 77.9% |
| 営業外収益 Non-operating income | 384 | 320 | △ 64 | 83.2% |
| 営業外費用 Non-operating expenses | 409 | 344 | △ 65 | 84.1% |
| 経常利益（△：損失） Ordinary income(Δ:loss) | 4,507 | 3,507 | △ 999 | 77.8% |
| 特別利益 Extraordinary gain | 1 | 41 | 40 | 4115.1% |
| 特別損失 Extraordinary loss | 12 | 23 | 10 | 186.8% |
| 税金等調整前当期純利益（△：損失） Income before income taxes(Δ:loss) | 4,496 | 3,526 | △ 970 | 78.4% |
| 法人税、住民税及び事業税 Current income taxes | 1,400 | 1,157 | △ 242 | 82.7% |
| 法人税等調整額 Deferred income taxes | 73 | △ 7 | △ 81 | ― |
| 当期純利益（△：損失） Net income(Δ:loss) | 3,022 | 2,375 | △ 646 | 78.6% |
| 非支配株主に帰属する当期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss) | 479 | 205 | △ 273 | 42.9% |
| 親会社株主に帰属する当期純利益（△：損失） Net income attributable to owners of the parent(Δ:loss) | 2,543 | 2,170 | △ 372 | 85.3% |
| 設備投資額（有形・無形） Capital expenditures | 1,162 | 2,696 | 1,534 | 232.0% |
| 減価償却費（有形・無形） Depreciation and Amortization | 1,013 | 1,434 | 420 | 141.5% |
| のれん償却額 Amortization of goodwill | 362 | 350 | △ 11 | 96.8% |

## 4. タカラバイオグループ :Takara Bio Group

### 要約損益計算書 :Statements of Income (Summary)

（百万円 :Millions of Yen）

| | 2019年3月期 FY2019 | 2020年3月期 FY2020 / Apr. 1, 2019 - Mar. 31, 2020 | 対前期 Change from FY2019 | |
|---|---|---|---|---|
| | 実績 Actual (a) | 実績 Actual (c) | 増減 Change (c-a) | 比 % (c/a) |
| 研究用試薬 Research reagents | 23,601 | 24,434 | 833 | 103.5% |
| 理化学機器 Scientific instruments | 2,570 | 1,242 | △ 1,328 | 48.3% |
| 受託・その他 Contracted service and other | 5,403 | 6,591 | 1,188 | 122.0% |
| バイオ産業支援　計 Bioindustry | 31,575 | 32,269 | 693 | 102.2% |
| 遺伝子医療 Gene Therapy | 2,443 | 2,295 | △ 147 | 94.0% |
| その他 Other | 1,822 | ― | △ 1,822 | ― |
| 売上高 Net sales | 35,841 | 34,565 | △ 1,275 | 96.4% |
| 売上原価 Cost of sales | 15,155 | 13,459 | △ 1,696 | 88.8% |
| 売上総利益 Gross profit | 20,685 | 21,105 | 420 | 102.0% |
| 運送費、保管料 Transportation and storage | 492 | 492 | 0 | 100.1% |
| 広告宣伝費 Advertising | 56 | 73 | 16 | 129.3% |
| 販売促進費 Sales promotion | 703 | 579 | △ 124 | 82.4% |
| 研究開発費 Research and development | 4,337 | 3,869 | △ 467 | 89.2% |
| 管理費、その他 Other, net | 9,632 | 9,816 | 183 | 101.9% |
| 販売費及び一般管理費 SG&A expenses | 15,221 | 14,830 | △ 390 | 97.4% |
| バイオ産業支援 Bioindustry | 7,100 | 7,748 | 648 | 109.1% |
| 遺伝子医療 Gene Therapy | 506 | 780 | 274 | 154.1% |
| その他 Other | △ 29 | ― | 29 | ― |
| 共通 Eliminations/Corporate | △ 2,114 | △ 2,254 | △ 140 | ― |
| 営業利益（△：損失） Operating income(Δ:loss) | 5,463 | 6,274 | 811 | 114.8% |
| 営業外収益 Non-operating income | 307 | 316 | 9 | 103.1% |
| 営業外費用 Non-operating expenses | 105 | 243 | 137 | 230.1% |
| 経常利益（△：損失） Ordinary income(Δ:loss) | 5,665 | 6,347 | 682 | 112.1% |
| 特別利益 Extraordinary income | 146 | 0 | △ 146 | 0.3% |
| 特別損失 Extraordinary loss | 988 | 914 | △ 73 | 92.5% |
| 税金等調整前当期純利益（△：損失） Income before income taxes(Δ:loss) | 4,823 | 5,433 | 610 | 112.7% |
| 法人税、住民税及び事業税 Current income taxes | 1,453 | 1,544 | 91 | 106.3% |
| 法人税等調整額 Deferred income taxes | △ 303 | 57 | 360 | ― |
| 当期純利益（△：損失） Net income(Δ:loss) | 3,673 | 3,831 | 158 | 104.3% |
| 非支配株主に帰属する当期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss) | 15 | 11 | △ 4 | 74.4% |
| 親会社株主に帰属する当期純利益（△：損失） Net income attributable to owners of the parent(Δ:loss) | 3,657 | 3,819 | 162 | 104.4% |
| 設備投資額（有形・無形） Capital expenditures | 6,002 | 5,365 | △ 637 | 89.4% |
| 減価償却費（有形・無形） Depreciation and Amortization | 2,691 | 2,921 | 230 | 108.6% |
| のれん償却額 Amortization of goodwill | 502 | 496 | △ 6 | 98.7% |

## 5. 6年間の財務サマリー（グループ別） :Six-Year Financial Summary by Business Group

### 宝ホールディングス（連結） :Takara Holdings Inc. -Consolidated-

（百万円 :Millions of Yen）

| | | 2015年3月期 FY2015 | 2016年3月期 FY2016 | 2017年3月期 FY2017 | 2018年3月期 FY2018 | 2019年3月期 FY2019 | 2020年3月期 FY2020 | 前期対比 Change from FY2019 増減 Change | 前期対比 Change from FY2019 比 YOY% |
|---|---|---|---|---|---|---|---|---|---|
| 売上高 | Net sales | 219,490 | 225,364 | 234,193 | 268,142 | 277,443 | 281,191 | 3,748 | 101.4% |
| 売上原価 | Cost of sales | 134,390 | 135,868 | 140,182 | 163,529 | 168,694 | 172,574 | 3,880 | 102.3% |
| （売上高原価率） | (Ratio to Net sales) | 61.2% | 60.3% | 59.9% | 61.0% | 60.8% | 61.4% | +0.6pt | – |
| 売上総利益 | Gross profit | 85,099 | 89,495 | 94,010 | 104,612 | 108,749 | 108,617 | △ 132 | 99.9% |
| 販売費及び一般管理費 | SG&A expenses | 74,003 | 77,815 | 80,458 | 88,999 | 90,945 | 92,781 | 1,835 | 102.0% |
| （売上高販管費率） | (Ratio to Net sales) | 33.7% | 34.5% | 34.4% | 33.2% | 32.8% | 33.0% | +0.2pt | – |
| 営業利益（△：損失） | Operating income(Δ:loss) | 11,096 | 11,680 | 13,551 | 15,612 | 17,804 | 15,836 | △ 1,967 | 88.9% |
| （売上高営業利益率） | (Ratio to Net Sales) | 5.1% | 5.2% | 5.8% | 5.8% | 6.4% | 5.6% | -0.8pt | – |
| 販売促進費、販売促進引当金繰入 | Sales promotion and allowance for s.p. | 32,818 | 33,471 | 34,292 | 33,688 | 34,012 | 35,073 | 1,060 | 103.1% |
| （売上高販促費率） | (Ratio to Net sales) | 15.0% | 14.9% | 14.6% | 12.6% | 12.3% | 12.5% | +0.2pt | – |
| 研究開発費 | R&D expenses | 3,754 | 4,608 | 4,550 | 5,063 | 4,708 | 4,259 | △ 449 | 90.5% |
| （売上高研究開発費率） | (Ratio to Net sales) | 1.7% | 2.0% | 1.9% | 1.9% | 1.7% | 1.5% | -0.2pt | – |
| 設備投資額（有形・無形） | Capital expenditures | 9,533 | 6,003 | 6,658 | 6,414 | 10,671 | 14,195 | 3,524 | 133.0% |
| 減価償却費（有形・無形） | Depreciation and Amortization | 4,662 | 5,179 | 5,171 | 6,430 | 6,490 | 7,626 | 1,136 | 117.5% |
| のれん償却額 | Amortization of goodwill | 500 | 538 | 586 | 843 | 865 | 847 | △ 18 | 97.9% |

### 宝酒造 :Takara Shuzo

（百万円 :Millions of Yen）

| | | 2015年3月期 FY2015 | 2016年3月期 FY2016 | 2017年3月期 FY2017 | 2018年3月期 FY2018 | 2019年3月期 FY2019 | 2020年3月期 FY2020 | 前期対比 Change from FY2019 増減 Change | 前期対比 Change from FY2019 比 YOY% |
|---|---|---|---|---|---|---|---|---|---|
| 売上高 | Net sales | – | – | 149,452 | 149,839 | 152,457 | 153,141 | 683 | 100.4% |
| 売上原価 | Cost of sales | – | – | 89,278 | 89,681 | 91,441 | 92,822 | 1,380 | 101.5% |
| （売上高原価率） | (Ratio to Net sales) | | | 59.7% | 59.9% | 60.0% | 60.6% | +0.6pt | – |
| 売上総利益 | Gross profit | | | 60,174 | 60,158 | 61,015 | 60,318 | △ 697 | 98.9% |
| 販売費及び一般管理費 | SG&A expenses | | | 55,103 | 54,589 | 55,067 | 56,142 | 1,075 | 102.0% |
| （売上高販管費率） | (Ratio to Net sales) | | | 36.9% | 36.4% | 36.1% | 36.7% | +0.5pt | – |
| 営業利益（△：損失） | Operating income(Δ:loss) | | | 5,071 | 5,569 | 5,948 | 4,175 | △ 1,772 | 70.2% |
| （売上高営業利益率） | (Ratio to Net sales) | | | 3.4% | 3.7% | 3.9% | 2.7% | -1.2pt | – |
| 販売促進費、販売促進引当金繰入 | Sales promotion and allowance for s.p. | | | 32,923 | 32,342 | 32,658 | 33,844 | 1,186 | 103.6% |
| （売上高販促費率） | (Ratio to Net sales) | | | 22.0% | 21.6% | 21.4% | 22.1% | +0.7pt | – |
| 設備投資額（有形・無形） | Capital expenditures | – | – | 2,188 | 2,696 | 3,128 | 5,520 | 2,391 | 176.5% |
| 減価償却費（有形・無形） | Depreciation and Amortization | – | – | 2,196 | 2,225 | 2,248 | 2,736 | 487 | 121.7% |

2018年3月期からの新セグメントです。
This is a new segment from the fiscal year ended March 2018.

### 宝酒造インターナショナルグループ :Takara Shuzo International Group

（百万円 :Millions of Yen）

| | | 2015年3月期 FY2015 | 2016年3月期 FY2016 | 2017年3月期 FY2017 | 2018年3月期 FY2018 | 2019年3月期 FY2019 | 2020年3月期 FY2020 | 前期対比 Change from FY2019 増減 Change | 前期対比 Change from FY2019 比 YOY% |
|---|---|---|---|---|---|---|---|---|---|
| 売上高 | Net sales | – | – | 37,540 | 70,717 | 77,834 | 82,765 | 4,931 | 106.3% |
| 売上原価 | Cost of sales | – | – | 25,641 | 49,843 | 54,823 | 58,882 | 4,058 | 107.4% |
| （売上高原価率） | (Ratio to Net sales) | – | – | 68.3% | 70.5% | 70.4% | 71.1% | +0.7pt | – |
| 売上総利益 | Gross profit | | | 11,899 | 20,874 | 23,010 | 23,883 | 872 | 103.8% |
| 販売費及び一般管理費 | SG&A expenses | | | 8,716 | 16,480 | 18,478 | 20,351 | 1,872 | 110.1% |
| （売上高販管費率） | (Ratio to Net sales) | | | 23.2% | 23.3% | 23.7% | 24.6% | +0.8pt | – |
| 営業利益（△：損失） | Operating income(Δ:loss) | | | 3,182 | 4,393 | 4,532 | 3,532 | △ 1,000 | 77.9% |
| （売上高営業利益率） | (Ratio to Net sales) | | | 8.5% | 6.2% | 5.8% | 4.3% | -1.6pt | – |
| 設備投資額（有形・無形） | Capital expenditures | – | – | 763 | 1,677 | 1,162 | 2,696 | 1,534 | 232.0% |
| 減価償却費（有形・無形） | Depreciation and Amortization | – | – | 623 | 938 | 1,013 | 1,434 | 420 | 141.5% |
| のれん償却額 | Amortization of goodwill | – | – | 424 | 353 | 362 | 350 | △ 11 | 96.8% |

2018年3月期からの新セグメントです。
This is a new segment from the fiscal year ended March 2018.

### タカラバイオグループ :Takara Bio Group

（百万円 :Millions of Yen）

| | | 2015年3月期 FY2015 | 2016年3月期 FY2016 | 2017年3月期 FY2017 | 2018年3月期 FY2018 | 2019年3月期 FY2019 | 2020年3月期 FY2020 | 前期対比 Change from FY2019 増減 Change | 前期対比 Change from FY2019 比 YOY% |
|---|---|---|---|---|---|---|---|---|---|
| 売上高 | Net sales | 25,969 | 29,729 | 29,375 | 32,312 | 35,841 | 34,565 | △ 1,275 | 96.4% |
| 売上原価 | Cost of sales | 12,142 | 13,405 | 12,422 | 13,657 | 15,155 | 13,459 | △ 1,696 | 88.8% |
| （売上高原価率） | (Ratio to Net sales) | 46.8% | 45.1% | 42.3% | 42.3% | 42.3% | 38.9% | -3.3pt | – |
| 売上総利益 | Gross profit | 13,827 | 16,323 | 16,952 | 18,655 | 20,685 | 21,105 | 420 | 102.0% |
| 販売費及び一般管理費 | SG&A expenses | 11,524 | 13,655 | 13,749 | 15,099 | 15,221 | 14,830 | △ 390 | 97.4% |
| （売上高販管費率） | (Ratio to Net sales) | 44.4% | 45.9% | 46.8% | 46.7% | 42.5% | 42.9% | +0.4pt | – |
| 営業利益（△：損失） | Operating income(Δ:loss) | 2,302 | 2,667 | 3,202 | 3,555 | 5,463 | 6,274 | 811 | 114.8% |
| （売上高営業利益率） | (Ratio to Net sales) | 8.9% | 9.0% | 10.9% | 11.0% | 15.2% | 18.2% | +2.9pt | – |
| 研究開発費 | R&D expenses | 3,401 | 4,275 | 4,101 | 4,653 | 4,337 | 3,869 | △ 467 | 89.2% |
| （売上高研究開発費率） | (Ratio to Net sales) | 13.1% | 14.4% | 14.0% | 14.4% | 12.1% | 11.2% | -0.9pt | – |
| 設備投資額（有形・無形） | Capital expenditures | 4,762 | 2,090 | 1,648 | 1,539 | 6,002 | 5,365 | △ 637 | 89.4% |
| 減価償却費（有形・無形） | Depreciation and Amortization | 1,347 | 1,687 | 1,722 | 2,568 | 2,691 | 2,921 | 230 | 108.6% |
| のれん償却額 | Amortization of goodwill | 136 | 181 | 162 | 489 | 502 | 496 | △ 6 | 98.7% |

## 6. 2020年3月期 参考資料 :Reference Data for the year ending March 31, 2020

### ① 為替前提及び売上高に対する為替レート変動の影響 :Exchange rates and effect of change in exchange rates on net sales

◆為替前提(海外子会社P/L換算用) :Exchange rates for the income statement of oversea subsidiaries

(円 : Yen)

| | 2019年3月期 FY2019 | 2020年3月期 FY2020 / Apr. 1, 2019 - Mar. 31, 2020 | |
|---|---|---|---|
| | 実績 Actual (a) | 実績 Actual (c) | 前期差 Change(c-a) |
| 米ドル : US dollar | 110.45 | 109.03 | △ 1.42 |
| ポンド: Pound | 147.40 | 139.19 | △ 8.21 |
| ユーロ: Euro | 130.35 | 122.03 | △ 8.32 |
| 人民元: Yuan | 16.71 | 15.77 | △ 0.94 |
| 100ウォン: 100 Won | 10.04 | 9.36 | △ 0.68 |
| インドルピー: Rupee | 1.62 | 1.55 | △ 0.07 |
| ｽｳｪｰﾃﾞﾝｸﾛｰﾅ :Sweden krona | 12.71 | 11.53 | △ 1.18 |
| ｼﾝｶﾞﾎﾟｰﾙﾄﾞﾙ :Singapore dollar | 81.86 | 79.93 | △ 1.93 |
| ｵｰｽﾄﾗﾘｱﾄﾞﾙ :Australian dollar | 82.55 | 75.78 | △ 6.77 |

◆売上高に対する為替レート変動の影響額 :Effect of change in exchange rates on net sales

| | 対前期 Change from FY2019 |
|---|---|
| 宝ホールディングス 計 Net sales of Takara Holdings Inc. -Consolidated- | △ 3,852 |
| うち宝酒造インターナショナルｸﾞﾙｰﾌﾟ Net sales of Takara Shuzo International Group | △ 3,075 |
| 海外酒類事業 Overseas Alcoholic beverages business | △ 308 |
| 海外日本食材卸事業 Japanese food wholesale business in overseas markets | △ 2,788 |
| その他 Other | ― |
| 連結消去 Elimination | 22 |
| うちタカラバイオグループ Net sales of Takara Bio Group | △ 787 |
| 研究用試薬 Research reagents | △ 726 |
| 理化学機器 Scientific instruments | △ 22 |
| 受託・その他 Contracted service and other | △ 38 |
| バイオ産業支援 計 Bioindustry | △ 787 |
| 遺伝子医療 Gene Therapy | ― |
| その他 Other | ― |

### ② 海外売上高比率の推移 :Change in overseas sales ratio

(百万円 :Millions of Yen)

| | 2019年3月期 実績 FY2019 Actual | | | 2020年3月期 実績 FY2020 Actual | | |
|---|---|---|---|---|---|---|
| | 売上高計 Net Sales | 海外売上高 Overseas Sales | 海外売上高比率 Overseas Sales Ratio | 売上高計 Net Sales | 海外売上高 Overseas Sales | 海外売上高比率 Overseas Sales Ratio |
| 宝酒造 Takara Shuzo | 152,457 | ― | ― | 153,141 | ― | ― |
| 宝酒造ｲﾝﾀｰﾅｼｮﾅﾙｸﾞﾙｰﾌﾟ Takara Shuzo International Group | 77,834 | 77,522 | 99.6% | 82,765 | 82,372 | 99.5% |
| タカラバイオグループ Takara Bio Group | 35,841 | 19,739 | 55.1% | 34,565 | 19,760 | 57.2% |
| その他および調整額 Other / Adjustment | 11,310 | ― | ― | 10,719 | ― | ― |
| 宝ホールディングス(連結) Takara Holdings Inc. -Consolidated- | 277,443 | 97,262 | 35.1% | 281,191 | 102,132 | 36.3% |

③ 海外主要子会社の業績 :Financial Forecast of major overseas subsidiaries

| | | 2019年3月期 実績 FY2019 Actual | | 2020年3月期 実績 FY2020 Actual | |
|---|---|---|---|---|---|
| | | 売上高 Net Sales | 営業利益 Operating income(Δ:loss) | 売上高 Net Sales | 営業利益 Operating income(Δ:loss) |
| 米国宝酒造 | 千 US ドル :Thousands of US dollar | 33,833 | 3,353 | 35,691 | 3,897 |
| Takara Sake USA Inc. | 百 万 円 :Millions of Yen | 3,736 | 370 | 3,891 | 424 |
| 宝酒造食品 | 千 元 :Thousands of Yuan | 56,398 | 3,975 | 57,258 | 4,867 |
| Takara Shuzo Foods Co.,Ltd. | 百 万 円 :Millions of Yen | 942 | 66 | 902 | 76 |
| トマーチン | 千 ポ ン ド :Thousands of Pound | 17,735 | 4,653 | 19,777 | 5,090 |
| The Tomatin Distillery Co.,Ltd | 百 万 円 :Millions of Yen | 2,614 | 685 | 2,752 | 708 |
| ｴｲｼﾞ・ｲﾝﾀｰﾅｼｮﾅﾙ | 千 US ドル :Thousands of US dollar | 23,646 | 9,659 | 26,990 | 12,045 |
| AGE INTERNATIONAL,INC. | 百 万 円 :Millions of Yen | 2,611 | 1,066 | 2,942 | 1,313 |
| フーデックスグループ | 千 ユ ー ロ :Thousands of Euro | 159,496 | 16,866 | 179,814 | 16,096 |
| FOODEX Group | 百 万 円 :Millions of Yen | 20,790 | 2,198 | 21,942 | 1,964 |
| タザキフーズ | 千 ポ ン ド :Thousands of Pound | 40,009 | 2,658 | 46,099 | 1,656 |
| TAZAKI FOODS LTD. | 百 万 円 :Millions of Yen | 5,897 | 391 | 6,416 | 230 |
| ミューチャルトレーディング | 千 US ドル :Thousands of US dollar | 341,215 | 11,906 | 369,212 | 6,224 |
| Mutual Trading Co., Inc. | 百 万 円 :Millions of Yen | 37,687 | 1,315 | 40,255 | 678 |
| ニッポンフード | 千 AUS ドル :Thousands of Australian dollar | 55,470 | 196 | 57,180 | △ 2,363 |
| Nippon Food Supplies Company Pty Ltd | 百 万 円 :Millions of Yen | 4,579 | 16 | 4,333 | △ 179 |
| ﾀｶﾗﾊﾞｲｵﾖｰﾛｯﾊﾟS.A.S. (連結) | 千 ユ ー ロ :Thousands of Euro | 25,795 | 1,877 | 25,324 | 1,184 |
| Takara Bio Europe S.A.S. Consolidated | 百 万 円 :Millions of Yen | 3,362 | 244 | 3,090 | 144 |
| 宝生物工程(大連) | 千 元 :Thousands of Yuan | 227,759 | 52,408 | 220,491 | 67,392 |
| Takara Biotechnology (Dalian) Co.,Ltd. | 百 万 円 :Millions of Yen | 3,805 | 875 | 3,477 | 1,062 |
| 宝日医生物技術(北京) | 千 元 :Thousands of Yuan | 366,339 | 63,288 | 404,484 | 77,614 |
| Takara Biomedical Technology(Beijing) Co., Ltd. | 百 万 円 :Millions of Yen | 6,121 | 1,057 | 6,378 | 1,223 |
| ﾀｶﾗｺﾘｱﾊﾞｲｵﾒﾃﾞｨｶﾙ | 百 万 ウ ォ ン :Millions of Won | 10,304 | 1,731 | 10,841 | 1,709 |
| Takara Korea Biomedical Inc. | 百 万 円 :Millions of Yen | 1,034 | 173 | 1,014 | 159 |
| タカラバイオDSSインド | 千 ｲﾝﾄﾞﾙﾋﾟｰ :Thousands of Rupee | 207,288 | 3,490 | 235,890 | 19,389 |
| DSS Takara Bio India Private Limited | 百 万 円 :Millions of Yen | 335 | 5 | 365 | 30 |
| タカラバイオUSA | 千 US ドル :Thousands of US dollar | 101,627 | 13,884 | 102,922 | 14,912 |
| Takara Bio USA, Inc. | 百 万 円 :Millions of Yen | 11,224 | 1,533 | 11,221 | 1,625 |

④ 宝酒造 売上総利益増減要因 :Factors of change in Gross profit of Takara Shuzo

(百万円 :Millions of Yen)

| | 対前期増減 Change from FY2019 | | |
|---|---|---|---|
| | 増減計 Total Change | 数量差 Change in quantities | 単価差 Change in unit price |
| 売上総利益 計 Gross profit | ▲697 | ▲95 | ▲602 |
| (主な内訳) | | | |
| 焼酎 Shochu | ▲1,497 | ▲1,428 | ▲69 |
| 清酒 Sake | ▲547 | ▲361 | ▲183 |
| ソフトアルコール飲料 Light-alcohol refreshers | +1,550 | +1,499 | +50 |
| 本みりん Hon Mirin | ▲48 | +72 | ▲120 |
| (参考)原価コストダウン Reference :Cost reduction | ▲867 | ※上記数量差および単価差に含む *Included in changes above | |

※利益の増加要因を「+」、減少要因を「△」で表示

*An increasing factor and a decreasing factor on profit are shown 「+」 and 「△」, respectively

⑤ 宝ホールディングス(連結)要約損益計算書(p.1)における「その他」の内訳

Breakdown of "Other" segment in the Consolidated Statements of Income of Takara Holdings Inc. (Summary) (p.1)

| | 2019年3月期 実績 FY2019 Actual | | 2020年3月期 実績 FY2020 Actual | |
|---|---|---|---|---|
| | 売上高 Net Sales | 営業利益 Operating income(Δ:loss) | 売上高 Net Sales | 営業利益 Operating income(Δ:loss) |
| 物流事業 Transportation | 13,981 | 577 | 14,243 | 598 |
| 宝ホールディングス(不動産事業) Takara Holdings (Real estate business) | 536 | 431 | 528 | 442 |
| その他 Other | 18,223 | 945 | 17,029 | 977 |
| 「その他」計 Total "Other" | 32,742 | 1,954 | 31,801 | 2,018 |

## 7. 2021年3月期 業績予想 :Financial forecast for the year ending March 31, 2021

① 宝ホールディングス(連結) :Takara Holdings Inc. -Consolidated-

(百万円 :Millions of Yen)

| | 2020年3月期 通期 実績 FY2020 Actual (a) | 2021年3月期 通期 予想 FY2021 Forecast (b) | 対前期 Change from FY2020 増減 Change (b-a) | 対前期 Change from FY2020 比 % (b/a) | 2020年3月期 第2四半期累計 実績 FY2020(1Q-2Q) Actual (c) | 2021年3月期 第2四半期累計 予想 FY2021(1Q-2Q) Forecast (d) | 対前期 Change from FY2020(1Q-2Q) 増減 Change (d-c) | 対前期 Change from FY2020(1Q-2Q) 比 % (d/c) |
|---|---|---|---|---|---|---|---|---|
| 宝酒造 Takara Shuzo | 153,141 | 155,157 | 2,015 | 101.3% | 75,135 | 74,428 | △ 707 | 99.1% |
| 宝酒造インターナショナルグループ Takara Shuzo International Group | 82,765 | 70,530 | △ 12,235 | 85.2% | 40,477 | 26,355 | △ 14,122 | 65.1% |
| タカラバイオ グループ Takara Bio Group | 34,565 | 33,800 | △ 765 | 97.8% | 16,450 | 14,365 | △ 2,085 | 87.3% |
| その他 Other | 31,801 | 31,716 | △ 85 | 99.7% | 15,770 | 14,889 | △ 881 | 94.4% |
| 調整額 Adjustment | △ 21,082 | △ 21,203 | △ 120 | — | △ 10,331 | △ 10,037 | 293 | — |
| 売上高 Net sales | 281,191 | 270,000 | △ 11,191 | 96.0% | 137,502 | 120,000 | △ 17,502 | 87.3% |
| 売上原価 Cost of sales | 172,574 | 163,700 | △ 8,874 | 94.9% | 84,468 | 73,400 | △ 11,068 | 86.9% |
| 売上総利益 Gross profit | 108,617 | 106,300 | △ 2,317 | 97.9% | 53,033 | 46,600 | △ 6,433 | 87.9% |
| 運送費、保管料 Transportation and storage | 11,000 | 11,100 | 99 | 100.9% | 5,206 | 4,900 | △ 306 | 94.1% |
| 広告宣伝費 Advertising | 2,051 | 2,100 | 48 | 102.4% | 952 | 1,000 | 47 | 105.0% |
| 販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p. | 35,073 | 35,000 | △ 73 | 99.8% | 17,011 | 17,100 | 88 | 100.5% |
| 研究開発費 Research and development | 4,259 | 5,300 | 1,040 | 124.4% | 2,057 | 2,600 | 542 | 126.4% |
| 管理費、その他 Other, net | 40,395 | 42,800 | 2,404 | 106.0% | 20,182 | 20,700 | 517 | 102.6% |
| 販売費及び一般管理費 SG&A expenses | 92,781 | 96,300 | 3,518 | 103.8% | 45,410 | 46,300 | 889 | 102.0% |
| 宝酒造 Takara Shuzo | 4,175 | 4,285 | 109 | 102.6% | 2,082 | 954 | △ 1,128 | 45.8% |
| 宝酒造インターナショナルグループ Takara Shuzo International Group | 3,532 | 145 | △ 3,387 | 4.1% | 1,565 | △ 1,952 | △ 3,517 | — |
| タカラバイオ グループ Takara Bio Group | 6,274 | 4,500 | △ 1,774 | 71.7% | 3,035 | 619 | △ 2,416 | 20.4% |
| その他 Other | 2,018 | 1,968 | △ 50 | 97.5% | 1,081 | 823 | △ 258 | 76.1% |
| 調整額 Adjustment | △ 164 | △ 898 | △ 733 | — | △ 140 | △ 144 | △ 3 | — |
| 営業利益(△:損失) Operating income(Δ:loss) | 15,836 | 10,000 | △ 5,836 | 63.1% | 7,623 | 300 | △ 7,323 | 3.9% |
| 受取利息・配当金 Interest and Dividends income | 911 | 700 | △ 211 | 76.8% | 472 | 300 | △ 172 | 63.5% |
| その他営業外収益 Other, net | 547 | 300 | △ 247 | 54.8% | 387 | 200 | △ 187 | 51.6% |
| 営業外収益 Non-operating income | 1,458 | 1,000 | △ 458 | 68.6% | 859 | 500 | △ 359 | 58.2% |
| 支払利息 Interest and discounts expenses | 403 | 400 | △ 3 | 99.1% | 203 | 200 | △ 3 | 98.2% |
| その他営業外費用 Other, net | 621 | 400 | △ 221 | 64.4% | 408 | 200 | △ 208 | 49.0% |
| 営業外費用 Non-operating expenses | 1,025 | 800 | △ 225 | 78.0% | 612 | 400 | △ 212 | 65.4% |
| 経常利益(△:損失) Ordinary income(Δ:loss) | 16,269 | 10,200 | △ 6,069 | 62.7% | 7,871 | 400 | △ 7,471 | 5.1% |
| 特別利益 Extraordinary gain | 1,473 | — | △ 1,473 | — | 40 | — | △ 40 | — |
| 特別損失 Extraordinary loss | 2,099 | 900 | △ 1,199 | 42.9% | 291 | 540 | 248 | 185.4% |
| 税金等調整前当期純利益(△:損失) Income(Δ:loss) before income taxes | 15,643 | 9,300 | △ 6,343 | 59.4% | 7,620 | △ 140 | △ 7,760 | — |
| 法人税、住民税及び事業税 Current income taxes | 5,077 | 3,300 | △ 1,652 | 66.6% | 2,288 | 190 | △ 2,145 | 8.1% |
| 法人税等調整額 Deferred income taxes | △ 125 | | | | 46 | | | |
| 当期純利益(△:損失) Net income(Δ:loss) | 10,691 | 6,000 | △ 4,691 | 56.1% | 5,285 | △ 330 | △ 5,615 | — |
| 非支配株主に帰属する当期純利益(△:損失) Net income attributable to the noncontrolling interest(Δ:loss) | 1,710 | 900 | △ 810 | 52.6% | 911 | △ 330 | △ 1,241 | — |
| 親会社株主に帰属する当期純利益(△:損失) Net income attributable to owners of the parent | 8,980 | 5,100 | △ 3,880 | 56.8% | 4,374 | 0 | △ 4,374 | — |
| 設備投資額(有形・無形) Capital expenditures | 14,195 | 14,020 | △ 175 | 98.8% | 8,421 | | | |
| 減価償却費(有形・無形) Depreciation and Amortization | 7,626 | 8,000 | 373 | 104.9% | 3,364 | 3,800 | 435 | 112.9% |
| のれん償却額 Amortization of goodwill | 847 | 850 | 2 | 100.3% | 424 | 420 | △ 4 | 99.0% |

② 宝酒造 :Takara Shuzo

（百万円 :Millions of Yen）

| | 2020年3月期 通期 実績 FY2020 Actual (a) | 2021年3月期 通期 予想 FY2021 Forecast (b) | 対前期 Change from FY2020 増減 Change (b-a) | 対前期 Change from FY2020 比 % (b/a) | 2020年3月期 第2四半期累計 実績 FY2020(1Q-2Q) Actual (c) | 2021年3月期 第2四半期累計 予想 FY2021(1Q-2Q) Forecast (d) | 対前期 Change from FY2020(1Q-2Q) 増減 Change (d-c) | 対前期 Change from FY2020(1Q-2Q) 比 % (d/c) |
|---|---|---|---|---|---|---|---|---|
| 焼酎 Shochu | 49,728 | 47,563 | △ 2,165 | 95.6% | 24,976 | 24,119 | △ 857 | 96.6% |
| 清酒 Sake | 20,488 | 19,047 | △ 1,441 | 93.0% | 8,302 | 7,150 | △ 1,152 | 86.1% |
| ソフトアルコール飲料 Light-alcohol refreshers | 43,023 | 48,467 | 5,443 | 112.7% | 21,744 | 24,057 | 2,312 | 110.6% |
| その他酒類 Other liquors | 6,405 | 5,825 | △ 580 | 90.9% | 3,259 | 2,754 | △ 505 | 84.5% |
| 本みりん Hon Mirin | 13,980 | 14,108 | 127 | 100.9% | 7,197 | 6,509 | △ 688 | 90.4% |
| その他調味料 Other seasonings | 10,330 | 10,566 | 235 | 102.3% | 5,140 | 5,064 | △ 76 | 98.5% |
| 原料用アルコール等 Raw alcohol | 9,183 | 9,581 | 397 | 104.3% | 4,514 | 4,775 | 260 | 105.8% |
| 売上高 Net sales | 153,141 | 155,157 | 2,015 | 101.3% | 75,135 | 74,428 | △ 707 | 99.1% |
| 売上原価 Cost of sales | 92,822 | 94,071 | 1,248 | 101.3% | 45,586 | 45,710 | 124 | 100.3% |
| 売上総利益 Gross profit | 60,318 | 61,086 | 767 | 101.3% | 29,549 | 28,717 | △ 832 | 97.2% |
| 運送費、保管料 Transportation and storage | 8,142 | 8,499 | 356 | 104.4% | 3,962 | 3,983 | 20 | 100.5% |
| 広告宣伝費 Advertising | 1,882 | 1,971 | 88 | 104.7% | 875 | 931 | 55 | 106.3% |
| 販売促進費、販売促進引当金繰入 Sales promotion and allowance for s.p. | 33,844 | 33,936 | 91 | 100.3% | 16,431 | 16,691 | 259 | 101.6% |
| 研究開発費 Research and development | 382 | 486 | 103 | 126.9% | 195 | 242 | 46 | 123.6% |
| 管理費、その他 Other, net | 11,890 | 11,909 | 18 | 100.2% | 6,002 | 5,916 | △ 86 | 98.6% |
| 販売費及び一般管理費 SG&A expenses | 56,142 | 56,801 | 658 | 101.2% | 27,467 | 27,763 | 295 | 101.1% |
| 営業利益（△：損失） Operating income(Δ:loss) | 4,175 | 4,285 | 109 | 102.6% | 2,082 | 954 | △ 1,128 | 45.8% |
| 営業外収益 Non-operating income | 236 | 212 | △ 24 | 89.5% | 255 | 145 | △ 110 | 56.7% |
| 営業外費用 Non-operating expenses | 299 | 288 | △ 11 | 96.3% | 198 | 151 | △ 47 | 76.0% |
| 経常利益（△：損失） Ordinary income(Δ:loss) | 4,113 | 4,209 | 95 | 102.3% | 2,139 | 948 | △ 1,191 | 44.3% |
| 特別利益 Extraordinary gain | 299 | — | △ 299 | — | 38 | — | △ 38 | — |
| 特別損失 Extraordinary loss | 564 | 229 | △ 335 | 40.6% | 194 | 33 | △ 161 | 16.9% |
| 税金等調整前当期純利益（△：損失） Income(Δ:loss) before income taxes | 3,848 | 3,980 | 131 | 103.4% | 1,982 | 915 | △ 1,067 | 46.2% |
| 法人税等 Current income taxes, etc. | 1,343 | 1,340 | 24 | 101.8% | 732 | 337 | △ 316 | 51.6% |
| 法人税等調整額 Deferred income taxes | △ 27 | | | | △ 79 | | | |
| 当期純利益（△：損失） Net income(Δ:loss) | 2,532 | 2,640 | 107 | 104.2% | 1,329 | 578 | △ 751 | 43.5% |
| 設備投資額（有形・無形） Capital expenditures | 5,520 | 1,937 | △ 3,583 | 35.1% | 4,004 | | | |
| 減価償却費（有形・無形） Depreciation and Amortization | 2,736 | 2,971 | 234 | 108.6% | 1,165 | 1,435 | 269 | 123.1% |

## ③ 宝酒造インターナショナルグループ :Takara Shuzo International Group

（百万円 :Millions of Yen）

| | 2020年3月期 通期 実績 FY2020 Actual (a) | 2021年3月期 通期 予想 FY2021 Forecast (b) | 対前期 Change from FY2020 増減 Change (b-a) | 対前期 Change from FY2020 比 % (b/a) | 2020年3月期 第2四半期累計 実績 FY2020(1Q-2Q) Actual (c) | 2021年3月期 第2四半期累計 予想 FY2021(1Q-2Q) Forecast (d) | 対前期 Change from FY2020(1Q-2Q) 増減 Change (d-c) | 対前期 Change from FY2020(1Q-2Q) 比 % (d/c) |
|---|---|---|---|---|---|---|---|---|
| 海外酒類事業 Overseas Alcoholic beverages business | 11,365 | 9,957 | △ 1,408 | 87.6% | 5,433 | 4,011 | △ 1,422 | 73.8% |
| 海外日本食材卸事業 Japanese food wholesale business in overseas markets | 73,371 | 62,546 | △ 10,825 | 85.2% | 36,097 | 23,173 | △ 12,924 | 64.2% |
| その他 Other | 204 | 68 | △ 136 | 33.2% | 179 | 44 | △ 135 | 24.5% |
| 連結消去 Elimination | △ 2,175 | △ 2,041 | 134 | — | △ 1,233 | △ 873 | 360 | — |
| 売上高 Net sales | 82,765 | 70,530 | △ 12,235 | 85.2% | 40,477 | 26,355 | △ 14,122 | 65.1% |
| 売上原価 Cost of sales | 58,882 | 49,244 | △ 9,638 | 83.6% | 28,994 | 18,507 | △ 10,487 | 63.8% |
| 売上総利益 Gross profit | 23,883 | 21,286 | △ 2,597 | 89.1% | 11,483 | 7,848 | △ 3,635 | 68.3% |
| 運送費、保管料 Transportation and storage | 2,656 | 2,347 | △ 309 | 88.4% | 1,203 | 855 | △ 348 | 71.0% |
| 広告宣伝費 Advertising | 84 | 92 | 7 | 109.0% | 40 | 41 | 0 | 100.0% |
| 販売促進費 Sales promotion | 756 | 731 | △ 25 | 96.7% | 334 | 278 | △ 56 | 83.1% |
| 管理費、その他 Other, net | 16,854 | 17,971 | 1,116 | 106.6% | 8,338 | 8,626 | 287 | 103.4% |
| 販売費及び一般管理費 SG&A expenses | 20,351 | 21,141 | 789 | 103.9% | 9,918 | 9,800 | △ 118 | 98.8% |
| 海外酒類事業 Overseas Alcoholic beverages business | 2,339 | 1,784 | △ 555 | 76.3% | 983 | 508 | △ 475 | 51.7% |
| 海外日本食材卸事業 Japanese food wholesale business in overseas markets | 2,735 | 21 | △ 2,714 | 0.8% | 1,367 | △ 1,628 | △ 2,995 | — |
| その他 Other | △ 853 | △ 1,165 | △ 311 | — | △ 364 | △ 563 | △ 198 | — |
| 連結消去 Elimination | △ 689 | △ 495 | 194 | — | △ 420 | △ 269 | 151 | — |
| 営業利益（△：損失） Operating income(Δ:loss) | 3,532 | 145 | △ 3,387 | 4.1% | 1,565 | △ 1,952 | △ 3,517 | — |
| 営業外収益 Non-operating income | 320 | 118 | △ 202 | 36.9% | 192 | 42 | △ 150 | 21.8% |
| 営業外費用 Non-operating expenses | 344 | 171 | △ 173 | 49.7% | 150 | 74 | △ 76 | 49.1% |
| 経常利益（△：損失） Ordinary income(Δ:loss) | 3,507 | 92 | △ 3,415 | 2.6% | 1,607 | △ 1,984 | △ 3,591 | — |
| 特別利益 Extraordinary gain | 41 | — | △ 41 | — | 1 | — | △ 1 | — |
| 特別損失 Extraordinary loss | 23 | — | △ 23 | — | 8 | — | △ 8 | — |
| 税金等調整前当期純利益（△：損失） Income(Δ:loss) before income taxes | 3,526 | 92 | △ 3,434 | 2.6% | 1,599 | △ 1,984 | △ 3,583 | — |
| 法人税等 Current income taxes, etc. | 1,157 | 213 | △ 937 | 18.5% | 485 | △ 426 | △ 881 | — |
| 法人税等調整額 Deferred income taxes | △ 7 | | | | △ 30 | | | |
| 当期純利益（△：損失） Net income(Δ:loss) | 2,375 | △ 121 | △ 2,496 | — | 1,144 | △ 1,558 | △ 2,702 | — |
| 非支配株主に帰属する当期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss) | 205 | △ 121 | △ 326 | — | 95 | △ 342 | △ 437 | — |
| 親会社株主に帰属する当期純利益（△：損失） Net income attributable to owners of the parent | 2,170 | 0 | △ 2,170 | — | 1,048 | △ 1,216 | △ 2,264 | — |
| 設備投資額（有形・無形） Capital expenditures | 2,696 | 2,631 | △ 65 | 97.6% | 908 | | | |
| 減価償却費（有形・無形） Depreciation and Amortization | 1,434 | 1,204 | △ 230 | 83.9% | 585 | 569 | △ 16 | 97.2% |
| のれん償却額 Amortization of goodwill | 350 | 371 | 20 | 105.7% | 173 | 185 | 11 | 106.4% |

④ タカラバイオグループ :Takara Bio Group

（百万円 :Millions of Yen）

| | 2020年3月期 通期 実績 FY2020 Actual (a) | 2021年3月期 通期 予想 FY2021 Forecast (b) | 対前期 Change from FY2020 増減 Change (b-a) | 対前期 Change from FY2020 比 % (b/a) | 2020年3月期 第2四半期累計 実績 FY2020(1Q-2Q) Actual (c) | 2021年3月期 第2四半期累計 予想 FY2021(1Q-2Q) Forecast (d) | 対前期 Change from FY2020(1Q-2Q) 増減 Change (d-c) | 対前期 Change from FY2020(1Q-2Q) 比 % (d/c) |
|---|---|---|---|---|---|---|---|---|
| 研究用試薬 Research reagents | 24,840 | 23,788 | △ 1,051 | 95.8% | 11,824 | 10,684 | △ 1,140 | 90.4% |
| 理化学機器 Scientific instruments | 1,242 | 1,178 | △ 64 | 94.8% | 620 | 477 | △ 142 | 77.0% |
| 受託サービス Contracted service | 6,186 | 7,201 | 1,014 | 116.4% | 1,961 | 2,734 | 772 | 139.4% |
| 遺伝子医療 Gene Therapy | 2,295 | 1,631 | △ 663 | 71.1% | 2,044 | 469 | △ 1,575 | 22.9% |
| 売上高 Net sales | 34,565 | 33,800 | △ 765 | 97.8% | 16,450 | 14,365 | △ 2,085 | 87.3% |
| 売上原価 Cost of sales | 13,459 | 12,999 | △ 459 | 96.6% | 6,121 | 5,721 | △ 400 | 93.5% |
| 売上総利益 Gross profit | 21,105 | 20,800 | △ 305 | 98.6% | 10,329 | 8,644 | △ 1,684 | 83.7% |
| 運送費、保管料 Transportation and storage | 492 | 588 | 96 | 119.5% | 186 | 275 | 89 | 148.0% |
| 広告宣伝費 Advertising | 73 | 77 | 4 | 105.8% | 33 | 36 | 3 | 109.0% |
| 販売促進費 Sales promotion | 579 | 551 | △ 27 | 95.2% | 299 | 244 | △ 54 | 81.8% |
| 研究開発費 Research and development | 3,869 | 4,814 | 945 | 124.4% | 1,858 | 2,357 | 498 | 126.8% |
| 管理費、その他 Other, net | 9,816 | 10,267 | 451 | 104.6% | 4,916 | 5,111 | 195 | 104.0% |
| 販売費及び一般管理費 SG&A expenses | 14,830 | 16,300 | 1,469 | 109.9% | 7,293 | 8,025 | 731 | 110.0% |
| 営業利益（△：損失） Operating income(Δ:loss) | 6,274 | 4,500 | △ 1,774 | 71.7% | 3,035 | 619 | △ 2,416 | 20.4% |
| 営業外収益 Non-operating income | 316 | 231 | △ 85 | 73.0% | 130 | 158 | 27 | 121.3% |
| 営業外費用 Non-operating expenses | 243 | 131 | △ 112 | 53.9% | 203 | 83 | △ 120 | 41.1% |
| 経常利益（△：損失） Ordinary income(Δ:loss) | 6,347 | 4,600 | △ 1,747 | 72.5% | 2,961 | 693 | △ 2,268 | 23.4% |
| 特別利益 Extraordinary gain | 0 | ― | △ 0 | ― | 0 | ― | △ 0 | ― |
| 特別損失 Extraordinary loss | 914 | 653 | △ 261 | 71.4% | 12 | 510 | 498 | 4205.7% |
| 税金等調整前当期純利益（△：損失） Income(Δ:loss) before income taxes | 5,433 | 3,946 | △ 1,487 | 72.6% | 2,950 | 182 | △ 2,767 | 6.2% |
| 法人税等 Current income taxes, etc. | 1,544 | 1,338 | △ 263 | 83.6% | 665 | 173 | △ 696 | 19.9% |
| 法人税等調整額 Deferred income taxes | 57 | | | | 205 | | | |
| 当期純利益（△：損失） Net income(Δ:loss) | 3,831 | 2,607 | △ 1,224 | 68.1% | 2,080 | 9 | △ 2,070 | 0.4% |
| 非支配株主に帰属する当期純利益（△：損失） Net income attributable to the noncontrolling interest(Δ:loss) | 11 | 7 | △ 4 | 65.3% | 4 | 9 | 4 | 195.3% |
| 親会社株主に帰属する当期純利益（△：損失） Net income attributable to owners of the parent | 3,819 | 2,600 | △ 1,219 | 68.1% | 2,075 | 0 | △ 2,075 | ― |
| 設備投資額（有形・無形） Capital expenditures | 5,365 | 8,813 | 3,447 | 164.3% | 3,190 | | | |
| 減価償却費（有形・無形） Depreciation and Amortization | 2,921 | 3,232 | 310 | 110.6% | 1,352 | 1,553 | 201 | 114.9% |
| のれん償却額 Amortization of goodwill | 496 | 477 | △ 18 | 96.3% | 250 | 238 | △ 11 | 95.4% |

## 8. 2021年3月期 参考資料 :Reference Data for the year ending March 31, 2021

### ① 為替前提及び売上高に対する為替レート変動の影響 :Exchange rates and effect of change in exchange rates on net sales

◆為替前提(海外子会社P/L換算用) :Exchange rates for the income statement of oversea subsidiaries

(円 : Yen)

| | 2020年3月期 FY2020 | 2021年3月期 FY2021 / Apr. 1, 2020 - Mar. 31, 2021 | |
|---|---|---|---|
| | 実績 Actual (a) | 予想 Forecast (b) | 前期差 Change(b-a) |
| 米ドル : US dollar | 109.03 | 105.00 | △ 4.03 |
| ポンド: Pound | 139.19 | 136.00 | △ 3.19 |
| ユーロ: Euro | 122.03 | 119.00 | △ 3.03 |
| 人民元: Yuan | 15.77 | 14.80 | △ 0.97 |
| 100ウォン: 100 Won | 9.36 | 8.80 | △ 0.56 |
| インドルピー: Rupee | 1.55 | 1.50 | △ 0.05 |
| ｽｳｪｰﾃﾞﾝｸﾛｰﾅ :Sweden krona | 11.53 | 11.90 | 0.37 |
| ｼﾝｶﾞﾎﾟｰﾙﾄﾞﾙ :Singapore dollar | 79.93 | 76.10 | △ 3.83 |
| ｵｰｽﾄﾗﾘｱﾄﾞﾙ :Australian dollar | 75.78 | 71.30 | △ 4.48 |

◆売上高に対する為替レート変動の影響額 :Effect of change in exchange rates on net sales

(百万円 :Millions of Yen)

| | 対前期 Change from FY2020 |
|---|---|
| 宝ホールディングス 計 Net sales of Takara Holdings Inc. -Consolidated- | △ 3,264 |
| 宝酒造インターナショナルｸﾞﾙｰﾌﾟ計 Net sales of Takara Shuzo International Group | △ 2,403 |
| 海外酒類事業 Overseas Alcoholic beverages business | △ 338 |
| 海外日本食材卸事業 Japanese food wholesale business in overseas markets | △ 2,123 |
| その他 Other | ― |
| 連結消去 Elimination | 58 |
| タカラバイオグループ 計 Net sales of Takara Bio Group | △ 869 |
| 研究用試薬 Research reagents | △ 798 |
| 理化学機器 Scientific instruments | △ 27 |
| 受託サービス Contracted service | △ 43 |
| 遺伝子医療 Gene Therapy | ― |

### ② 海外売上高比率の推移 :Change in overseas sales ratio

(百万円 :Millions of Yen)

| | 2020年3月期通期実績 FY2020 Actual | | | 2021年3月期通期予想 FY2021 Forecast | | |
|---|---|---|---|---|---|---|
| | 売上高計 Net Sales | 海外売上高 Overseas Sales | 海外売上高比率 Overseas Sales Ratio | 売上高計 Net Sales | 海外売上高 Overseas Sales | 海外売上高比率 Overseas Sales Ratio |
| 宝酒造 Takara Shuzo | 153,141 | ― | ― | 155,157 | ― | ― |
| 宝酒造ｲﾝﾀｰﾅｼｮﾅﾙｸﾞﾙｰﾌﾟ Takara Shuzo International Group | 82,765 | 82,372 | 99.5% | 70,530 | 70,092 | 99.4% |
| タカラバイオグループ Takara Bio Group | 34,565 | 19,760 | 57.2% | 33,800 | 19,137 | 56.6% |
| その他および調整額 Other / Adjustment | 10,719 | ― | ― | 10,513 | ― | ― |
| 宝ホールディングス(連結) Takara Holdings Inc. -Consolidated- | 281,191 | 102,132 | 36.3% | 270,000 | 89,229 | 33.0% |

③ 海外主要子会社の業績 :Financial Forecast of major overseas subsidiaries

| | | 2020年3月期 実績 FY2020 Actual | | 2021年3月期 予想 FY2021 Forecast | |
|---|---|---|---|---|---|
| | | 売上高 Net Sales | 営業利益 Operating income(Δ:loss) | 売上高 Net Sales | 営業利益 Operating income(Δ:loss) |
| 米国宝酒造 | 千 US ドル :Thousands of US dollar | 35,691 | 3,897 | 30,505 | 1,626 |
| Takara Sake USA Inc. | 百 万 円 :Millions of Yen | 3,891 | 424 | 3,203 | 170 |
| 宝酒造食品 | 千 元 :Thousands of Yuan | 57,258 | 4,867 | 51,366 | 3,226 |
| Takara Shuzo Foods Co.,Ltd. | 百 万 円 :Millions of Yen | 902 | 76 | 760 | 47 |
| トマーチン | 千 ポ ン ド :Thousands of Pound | 19,777 | 5,090 | 17,857 | 4,420 |
| The Tomatin Distillery Co.,Ltd | 百 万 円 :Millions of Yen | 2,752 | 708 | 2,428 | 601 |
| ｴｲｼﾞ・ｲﾝﾀｰﾅｼｮﾅﾙ | 千 US ドル :Thousands of US dollar | 26,990 | 12,045 | 26,107 | 11,276 |
| AGE INTERNATIONAL,INC. | 百 万 円 :Millions of Yen | 2,942 | 1,313 | 2,741 | 1,184 |
| フーデックスグループ | 千 ユ ー ロ :Thousands of Euro | 179,814 | 16,096 | 153,289 | 5,800 |
| FOODEX Group | 百 万 円 :Millions of Yen | 21,942 | 1,964 | 18,241 | 690 |
| タザキフーズ | 千 ポ ン ド :Thousands of Pound | 46,099 | 1,656 | 41,461 | 729 |
| TAZAKI FOODS LTD. | 百 万 円 :Millions of Yen | 6,416 | 230 | 5,638 | 99 |
| ミューチャルトレーディング | 千 US ドル :Thousands of US dollar | 369,212 | 6,224 | 321,365 | △ 9,351 |
| Mutual Trading Co., Inc. | 百 万 円 :Millions of Yen | 40,255 | 678 | 33,743 | △ 981 |
| ニッポンフード | 千 AUS ドル :Thousands of Australian dollar | 57,180 | △ 2,363 | 51,792 | △ 1,566 |
| Nippon Food Supplies Company Pty Ltd | 百 万 円 :Millions of Yen | 4,333 | △ 179 | 3,692 | △ 111 |
| ﾀｶﾗﾊﾞｲｵﾖｰﾛｯﾊﾟS.A.S. (連結) | 千 ユ ー ロ :Thousands of Euro | 25,324 | 1,184 | 27,872 | 2,003 |
| Takara Bio Europe S.A.S. Consolidated | 百 万 円 :Millions of Yen | 3,090 | 144 | 3,316 | 238 |
| 宝生物工程(大連) | 千 元 :Thousands of Yuan | 220,491 | 67,392 | 276,214 | 95,240 |
| Takara Biotechnology (Dalian) Co.,Ltd. | 百 万 円 :Millions of Yen | 3,477 | 1,062 | 4,087 | 1,409 |
| 宝日医生物技術(北京) | 千 元 :Thousands of Yuan | 404,484 | 77,614 | 406,955 | 62,520 |
| Takara Biomedical Technology(Beijing) Co., Ltd. | 百 万 円 :Millions of Yen | 6,378 | 1,223 | 6,022 | 925 |
| ﾀｶﾗｺﾘｱﾊﾞｲｵﾒﾃﾞｨｶﾙ | 百 万 ウ ォ ン :Millions of Won | 10,841 | 1,709 | 11,488 | 1,769 |
| Takara Korea Biomedical Inc. | 百 万 円 :Millions of Yen | 1,014 | 159 | 1,010 | 155 |
| タカラバイオDSSインド | 千 ｲﾝﾄﾞﾙﾋﾟｰ :Thousands of Rupee | 235,890 | 19,389 | 313,021 | 17,325 |
| DSS Takara Bio India Private Limited | 百 万 円 :Millions of Yen | 365 | 30 | 469 | 25 |
| タカラバイオUSA | 千 US ドル :Thousands of US dollar | 102,922 | 14,912 | 96,910 | 3,436 |
| Takara Bio USA, Inc. | 百 万 円 :Millions of Yen | 11,221 | 1,625 | 10,175 | 360 |

④ 宝酒造 売上総利益増減要因 :Factors of change in Gross profit of Takara Shuzo

(百万円 :Millions of Yen)

| | 対前期増減 Change from FY2020 | | |
|---|---|---|---|
| | 増減計 Total Change | 数量差 Change in quantities | 単価差 Change in unit price |
| 売上総利益 計 Gross profit | +767 | +1,663 | ▲895 |
| (主な内訳) | | | |
| 焼酎 Shochu | ▲878 | ▲788 | ▲89 |
| 清酒 Sake | ▲777 | ▲439 | ▲337 |
| ｿﾌﾄｱﾙｺｰﾙ飲料 Light-alcohol refreshers | +2,210 | +2,244 | ▲34 |
| 本みりん Hon Mirin | ▲68 | +55 | ▲124 |
| (参考)原価コストダウン Reference :Cost reduction | ▲280 | ※上記数量差および単価差に含む *Included in changes above | |

※利益の増加要因を「+」、減少要因を「△」で表示

*An increasing factor and a decreasing factor on profit are shown 「+」 and 「△」, respectively

⑤ 宝ホールディングス(連結)業績予想(p.10)における「その他」の内訳 :Breakdown of "Other" segment in the Financial forecast of Takara Holdings Inc. (p.10)

| | 2020年3月期 実績 FY2020 Actual | | 2021年3月期 予想 FY2021 Forecast | |
|---|---|---|---|---|
| | 売上高 Net Sales | 営業利益 Operating income(Δ:loss) | 売上高 Net Sales | 営業利益 Operating income(Δ:loss) |
| 物流事業 Transportation | 14,243 | 598 | 14,521 | 588 |
| 宝ホールディングス(不動産事業) Takara Holdings (Real estate business) | 528 | 442 | 511 | 424 |
| その他 Other | 17,029 | 977 | 16,682 | 955 |
| 「その他」計 Total "Other" | 31,801 | 2,018 | 31,716 | 1,968 |